Quarterlytics / Technology / Integrated Research Limited

Integrated Research Limited

iri · ASX Technology
Claim this profile
Ticker iri
Exchange ASX
Sector Technology
Industry
Employees 201-500
← All annual reports
FY2016 Annual Report · Integrated Research Limited
Sign in to download
Loading PDF…
Integrated Research
Annual Report 2016

ABN 76 003 588 449

I

n

t

e

g

r

a

t

e

d

R

e

s

e

a

r

c

h

A

n

n

u

a

l

R

e

p

o

r

t

2

0

1

6

Asia Pacifi c/Middle East/Africa

Integrated Research Limited

Level 9, 100 Pacifi c Highway

North Sydney NSW 2060

Australia

T. +61 (2) 9966 1066

F. +61 (2) 9966 1042

E. info.ap@ir.com

Singapore

Unit 12‑01, Palais Renaissance

390 Orchard Road

Singapore 238871

T. +65 6684 5856

E. info.ap@ir.com

United Kingdom & Ireland

Integrated Research UK Ltd

The Atrium, Harefi eld Road

Uxbridge, Middlesex

UB8 1PH

United Kingdom

T. +44 (0) 189 581 7800

E. info.europe@ir.com

Terminalstrasse Mitte 18

85356 Munchen, Germany

T. +49 (89) 97 007 132

E. info.germany@ir.com

Integrated Research (Singapore) Pte. Ltd.

Integrated Research Germany GmbH

Integrated Research, Inc.

Germany

Americas ‑ East Coast

Americas ‑ West Coast

Integrated Research, Inc.

6312 S. Fiddlers Green Circle, Suite 500N

Denver, CO 80111, USA

T: +1 (303) 390 8700

F: +1 (303) 390 877

E. info.usa@ir.com

12950 Worldgate Dr, Suite 720

Herndon, VA 20170, USA

T: +1 (303) 390 8700

F: +1 (303) 390 8777

E. info.usa@ir.com

Americas ‑ Mid West

Integrated Research, Inc.

6601 Lyndale Ave. S., Suite 330

Richfi eld, Minnesota, MN 55423, USA

T. +1 (612) 243 6700 

F. +1 (303) 390 8777

E. info.usa@ir.com

ir.com

 
 
 
 
Nothing is as constant as change.

As IR celebrates another year of record growth 
we’re making sure our global customers can 
interact and transact in a frictionless way.

In the age of digital transformation we bring 
a thousand points of reference into a single 
point of view.

Corporate

directory

Directors

Steve Killelea

Non‑Executive Director & Chairman

Darc Dencker‑Rasmussen

Managing Director & CEO

Share Registry

Computershare

Solicitors

Ashurst

Level 11, 5 Martin Place

Sydney NSW 2000

Nick Abrahams

Non‑Executive Director

Alan Baxter

Non‑Executive Director

Paul Brandling

Non‑Executive Director

Garry Dinnie

Non‑Executive Director

Peter Lloyd

Non‑Executive Director

Company Secretary

David Purdue

Registered Offi  ce

Level 9, 100 Pacifi c Highway

North Sydney NSW 2060

T. +61 (2) 9966 1066

Bankers

National Australia Bank

Westpac Banking Corporation

Securities Exchange Listing

Australian Securities Exchange

Code: IRI

Country of Incorporation

Integrated Research Limited,

incorporated and domiciled in

Australia, is a publicly listed

company limited by shares.

Notice of Annual General Meeting

The Annual General Meeting of

Integrated Research Limited will be

held on:

The Mint

at 3:00pm

Friday 25 November 2016

10 Macquarie Street, Sydney

This Annual Report is printed on Titan Plus Satin. Fibre is sourced from certifi ed and well managed forests in compliance with the
environmental and social standards of the FSC® Council.

4847 Designed and Produced by RDA Creative www.rda.com.au

Contents

CEO’s report

2016 highlights

Chairman’s letter

3  
4  
6  
9 
11  
13   Directors’ report
27  Remuneration report (audited)

About Integrated Research

Marketing highlights

38   Corporate governance
45   Financials
79   Directors’ declaration
80   Independent auditor’s report
83   ASX additional information
85   Corporate directory

1

Integrated Research and its controlled entities Annual Report 2016Achievements

Global 
recognition 
by Gartner 
& Aragon 
Research

UC

 39%

Regional

Europe  58%
Asia Pacific  16%

Consulting

7th consecutive 
year

120 

Fortune 500 Customers

Total Revenue

 20%

2

Integrated Research and its controlled entities Annual Report 2016

Financial highlights

10/10

Top US Banks 

6/10

Top Fin Services 
Companies Globally 

6/10

Top Automotive Companies 

IN MILLIONS OF AUD (EXCEPT EARNINGS PER SHARE)

Year ended 30 June

2016

2015

% Change

Revenue from licence fees

 45.7 

 41.0 

11% 

Total revenue

Net profit after tax

Net assets

 84.5 

 70.3 

20% 

 16.0 

 14.3 

12% 

 41.0 

 36.1 

14% 

Cash at balance date

 8.5 

 15.3 

‑44% 

Americas revenue

Europe revenue

 58.0 

 52.7 

10% 

 17.2 

 10.2 

69% 

Asia Pacific revenue

 10.3 

 8.9 

Earnings per share (cents per share)

 9.4 

 8.4 

16% 

12% 

6/10

Biggest Telcos

Year ended 30 June

2016

2015

% Change

Americas revenue (USD)

 42.0 

 43.6 

‑4% 

Europe revenue (UK Sterling)

 8.4 

 5.3 

58% 

Asia Pacific revenue (AUD)

 10.3 

 8.9 

16% 

Total revenue  
(AUD millions)

Net profit after tax  
(AUD millions)

Revenue from licence sales 
(AUD millions)

48.6

48.9

53.2

70.3

84.5

9.0

9.1

8.5

14.3

16.0

28.9

26.6

28.0

41.0

45.7

2012 2013 2014 2015

2016

2012 2013 2014 2015

2016

2012 2013 2014 2015

2016

Integrated Research and its controlled entities Annual Report 2016

3

Letter from
the Chairman

It is my pleasure to comment on another record 
performance of Integrated Research for the financial 
year to 30 June 2016. It is particularly pleasing to 
see that the investments made in both Europe and 
Asia are bearing fruit, and the Company is recording 
high growth both in profit and revenue to further 
cement its leading global position. 

Dear fellow shareholders, 

The Company achieved an increase 
of 12% in net profit after tax over 
the prior year to $16.0 million; 
licence sales increased by 11% 
and total revenue increased by 
20% to $84.5 million with revenue 
coming from a wide range of 
customers, products and regions. 
This underscores the strength of the 
Company’s global business, with over 
95% of its revenue being derived 
outside Australia. 

Europe revenues grew by 58% to 
£8.4 million and Asia Pacific revenue 
increased by 16% to $10.3 million 
driven by licence sales growth 
primarily in unified communications. 
The Americas delivered a solid 
performance with revenue of 
US$42.0 million with underlying 
growth achieved in Skype for 
Business and Contact Centres. 

IR Consulting Services achieved 
a 7th consecutive year of growth, 
with revenue increasing by 33% to 
$7.4 million.

The Company cemented its 
leadership position in Unified 
Communications achieving a 
number of significant awards 
and citations. Gartner, the world’s 
leading information technology 
research advisory company named 
Integrated Research a Cool Vendor 

in the “Cool Vendors in Availability 
and Performance, 2016” report. 
IR was the only UC Performance 
Management Vendor awarded 
this distinction.

Integrated Research was also 
named the only ‘Hot Vendor’ by 
Aragon Research in the Unified 
Communications and Collaboration 
segment. Aragon Research selects 
Hot Vendors across multiple markets 
that are unique technological leaders 
and recognized Integrated Research 
for its ability to manage highly 
complex UC environments across 
multiple vendors.

2016 marks the 8th consecutive year 
of growth in Unified Communications 
increasing on the prior year by 39% 
to $50.8 million. Prognosis sales to 
customers using Skype for Business 
was a significant contributor to 
this and represents a major growth 
opportunity in the future. 

Over the past year the Company 
has collaborated with Cisco to 
achieve compliance with both the 
US Government Federal Information 
Processing Standards and the 
Federal Risk and Authorization 
Management Program. 
The Company has now secured 
initial contractual arrangements 
for the supply of solutions to the 
US Federal Government. 

4

Integrated Research and its controlled entities Annual Report 2016Annual revenue  20%

$84.5M

The future outlook for IR remains 
strong. The Company’s growth 
strategy is to create, sell and 
support Prognosis‑based products 
and services that deliver profitable 
growth from existing markets and 
customers, as well as creating new 
products that open new markets.  

The Board is pleased to announce a 
final dividend of 3.5 cents per share 
franked to 60% bringing the total 
dividend for the year to 6.5 cents per 
share franked at 58%. This compares 
with total dividends of 7.5 cents per 
share franked at 35 % for the prior 
financial year. 

I would especially like to thank you, 
our valued shareholders, for your 
continued support. 

Steve Killelea 
Chairman

Successful implementation should 
result in the addition of many millions 
of users, creating strong growth in 
future years. Integrated Research 
already has contracts for supply 
to the US Department of Justice, 
US Customs and Border Protection, 
Department of the Treasury and 
other Federal and State Government 
Agencies. According to the US 
Bureau of Labor Statistics, as of 
April 2016 more than 22 million 
people were employed in the 
US government.

Payments revenue rose 10% over 
the previous year with strong licence 
sale growth coming from the UK. 
The Company has expanded its 
suite of Payments solutions by 
adding new products including 
fraud management, payments 
analytics and wholesale money 
transfer applications. Development 
innovations in Payments will enable 
visibility into new technology roll‑outs 
such as Apple Pay. 

After the above‑trend performance 
in HP Non‑Stop revenues for FY2015, 
the high margin Infrastructure product 
line delivered $20.8 million in revenue 
for FY2016, consistent with the 
previous 5‑year average. The annual 
revenue from the Infrastructure 
product line is highly aligned to the 
underlying licence renewal profile. 
The 2017 renewals should assist in 
underpinning a good performance for 
the FY17 financial year.

The Company remains focused 
on sustaining its competitive 
advantage through continuing 
innovation that comes from its 
research and development program. 
Research and development 
expenditure of $13.6 million was 16% 
of total revenue, which underlines 
the company’s commitment to 
technical excellence. Prognosis 11 
was released in June 2016 and will 
provide the Company with further 
growth opportunities. 

The Company continues to focus 
on expanding its capabilities 
and improving productivity. 
Total expenses were $64.5 million, 
up 22% against the prior year. 
The increase in cost was driven 
by three factors. Firstly, the 
annualisation of investments 
made part way through the 2015 
financial year; secondly additional 
cost carried from the acquisition 
of the Testing Solutions business; 
and thirdly the higher cost base 
driven through a lower Australian 
dollar giving rise to higher offshore 
translated costs. 

On 1 July 2015 IR completed the 
acquisition of US based IQ Services. 
The integration of the acquisition is 
substantially complete. The Company 
achieved $4.3 million in revenue 
from the Testing solution line and the 
deferred revenue backlog grew by 
132% over the course of the year.

5

Integrated Research and its controlled entities Annual Report 2016Chief Executive
Officer’s Report

The Company’s deep engagement with its 
customers and an understanding of what they 
need to support their success has resulted in 
strong recurring revenue streams. Strategic 
investments made in 2015 into Europe have 
paid off in 2016 with revenue growing by 58%.

Dear shareholders, 

The Company once again delivered 
record revenues and profits in 2016. 
This consistent result is a strong 
indicator of the success of the four 
strategic initiatives the Company 
commenced in 2014: To create 
agile and innovative solutions, 
leverage growth through partners, 
grow momentum through strategic 
marketing and build regional growth.

In 2015 the Company started a 
three‑year transition to reduce the 
number of one‑off perpetual licence 
sales and correspondingly increase 
the number of recurring term 
licences. Recurring term licences 
create a compounding growth base 
that underpins future performance 
and growth.

The Company has now completed 
two years of the three‑year transition 
from perpetual to recurring term 
arrangements. The Company has 
managed to show healthy growth 
through each of the first two 
bridging years despite the lower 
initial cashflow of recurring term 
arrangements. The three‑year term 
licences that were signed in 2015 
become due for renewal in 2018 
and the Company expects that will 
provide a platform for solid cash flow 
and revenue growth acceleration 
over and above what was achieved in 
past years. 

Prognosis has proven to be a sticky 
solution in the past, with historical 
renewal rates of above 90%. 
To maximize the benefits of renewals, 
the Company will continue to focus 
on activities that will support high 
renewal rates. These activities include 
focused account management 
to ensure customer adoption and 
satisfaction as well as expanding 
share of wallet. 

Analysis of the Company’s base of 
over 1,200 enterprise customers 
shows significant potential to expand 
the number of IR solutions sold to 
each customer. Prognosis is a modular 
solution and customers will typically 
purchase a subset of those modules 
in their initial purchase. Subsequent 
purchases may include additional 
solutions such as Reporting and 
Analytics, Video Management, Testing 
Solutions, Contact Centre and Call 
Recording Assurance to name some 
of the most commonly applicable. 
These additional modules provide the 
opportunity significant upsell. 

Strong recurring revenue streams are 
supported by the Company’s deep 
engagement with its customers and 
an understanding of what they need 
to support their success. Prognosis 11, 
released in June 2016, was built using 
that insight. Prognosis 11 product 
enhancements in Call Recording 
Assurance, Skype for Business and 
Unified Communications for cloud and 
service providers should see revenue 
realisation in the 2017 financial year 

6

Integrated Research and its controlled entities Annual Report 2016Annual after tax profit  12%

$16.0M

and beyond. In addition, the Company 
is now the only vendor to maintain 
current certification across all the 
major Unified Communications 
platforms, namely Cisco, Avaya and 
Microsoft Skype for Business.

Skype for Business is the fastest 
growing solution in Microsoft’s history 
and Prognosis sales to customers 
using Skype for Business was a 
significant contributor to the 39% 
growth in the Company’s Unified 
Communications (UC) product line 
this year. It also represents a major 
future growth opportunity for the 
Company in years to come. IR has 
been a trusted Microsoft Unified 
Communications partner since 2010. 
In addition to the Company’s status 
as a Microsoft Gold Partner it is one 
of very few companies certified 
specifically for Skype for Business. It is 
also the only solution recommended 
by Microsoft for both the Essentials 
and Advanced categories of its 
Skype Operations Framework ‑ the 
best practices framework for the 
implementation of the solution. 
This partnership with Microsoft 
validates the importance of Prognosis 
in the successful deployment of the 
Microsoft Skype for Business solution.

As companies like Apple, Samsung, 
Google and others offer the latest 
advancements in payments and 
financial technology, the payments 
processing industry must adapt 
to these new challenges and 
customer demands. New Prognosis 
payment capabilities were delivered 
in Prognosis 11 this year, providing 
visibility and management of new 
technology roll outs of tokenized 
transactions like Apple Pay. 
These capabilities build on more than 
a decade of experience in helping 
customers de‑risk deployments of 
new technology and help them 
realize the benefits from their 
investment sooner. The Company has 
a significant growth opportunity as 
these disruptive payments methods 
become mainstream. 

The Company’s strategic investments 
made in 2015 into Europe paid off 
in 2016 with revenue growing by 
58% to £8.4 million. The growth was 
across both the UK and Continental 
Europe with key wins in both Unified 
Communications and Payments. 
The key account wins included large 
engagements with Barclaycard, 
HSBC, Nationwide Building Society 
and T‑Systems. 

All these elements combine to support 
the Company’s objective to sustain and 
exceed the high growth rate achieved 
in the Unified Communications product 
line with an eight‑year compound 
annual growth rate of 24%.

While investment in the Singapore 
office started somewhat later than 
in Europe, it enabled Asia Pacific to 
grow revenue by 16% to $10.3 million. 
The licence growth was delivered 
across Infrastructure and UC products.

Our highly successful strategic 
marketing initiative ensured that 
we reached more people with 
our solutions, our brand and our 
successes. Our global reach has 
expanded with website, collateral 
and social media engagement in 
languages like German, Chinese 
and Spanish. The Company was also 
recognised for its thought leadership 
by both Gartner and Aragon Research 
as well as in 68 editorial media articles 
written about the Company and the 
value its solutions deliver to customers. 

Management would like to recognise 
and thank the highly talented and 
professional team of employees 
who make the Company’s ongoing 
success possible. We also thank 
you, our fellow shareholders, for 
supporting the Management team 
and employees in their endeavours to 
innovate, grow and build sustainable 
market leading value. 

Darc Rasmussen  
CEO & Managing Director

7

Integrated Research and its controlled entities Annual Report 2016Minneapolis (MN)

Denver (CO)

Washington (DC)

London

Munich

Sydney

Singapore

IR is a truly global company

8
8

Integrated Research and its controlled entities Annual Report 2016

Integrated Research and its controlled entities Annual Report 2016About IR

IR is the corporate brand name of Integrated 
Research Limited, the leading global provider of 
experience management solutions for unified 
communications, contact centres and critical 
IT infrastructure. 

What we do

Our vision

IR designs, develops, markets, 
sells and implements IR Prognosis 
solutions to a cross section of the 
world’s largest organisations. 

To make the world a smarter, 
easier place to live and work in, 
where people and technology 
interact in a frictionless way.

For almost 3 decades we have 
provided real‑time, fault‑tolerant 
management for business‑critical 
computer systems and applications.

Why customers buy

IR Prognosis provides best in class 
user and customer experience 
management that optimizes 
operations of mission critical systems 
through insight into real time and 
historical events. 

Prognosis helps systems run fluidly 
at the highest level of optimisation 
giving our customers total control 
over their entire eco‑system

Why we succeed

We help organisations replace 
reactive, hands‑on systems 
and procedures with proactive, 
automated systems for 
performance management.

Prognosis works to identify areas 
where problems are brewing or may 
occur in the future, pro‑actively 
avoiding disruptions in service to 
hundreds of millions of people on 
a daily basis.

Our mission

To create innovative technology 
that optimises operations, predicts 
business disruption and automates 
the steps to improve the experience 
of every interaction.

Our brand

The IR brand uses dots and dashes 
to convey ideas in simple and 
engaging ways.

We focus on the challenges our 
customers face and the solutions we 
provide. We don’t over complicate 
things because simplicity is key and 
less is more.

Our momentum

Our products have stood the 
test of time, and we have always 
invested for the future to innovate, 
grow and build sustainable market 
leading value. 

Over the past 12 months our R&D 
team has delivered breakthrough 
innovations in exciting areas such as 
anomaly detection and self‑healing. 
These and many more will deliver new 
revenue streams and ensure that IR 
remains the market leader. 

9

Integrated Research and its controlled entities Annual Report 2016Performance Management Innovation

g

t i m i s i n

p

O

SELF HEALING
Taking action and
learning how to adapt

o r y

c t

T r a j e

PREDICTION
Forecasting and
predicting future events

Automation

Learning

Prediction

Prescription

INSIGHT
Establishing patterns
and causality

Root Cause

Analytics

g

F i x i n

VISIBILITY
Real-time and historical
events and data

Visibility

1010

Integrated Research and its controlled entities Annual Report 2016

Integrated Research and its controlled entities Annual Report 2016Innovation is at the heart of IR
IR employees’ innovative thinking and deep domain expertise delivers real 
value as we help our customers replace reactive, hands‑on systems and 
procedures with proactive, automated solutions.

These solutions deliver meaningful improvements and help our customers progress towards greater operational maturity. 
This means better customer experiences and when we deliver them, we’re fulfilling our vision. By helping people and 
technology interact in a frictionless way, we’re making the world a smarter and easier place to live and work in.

Gartner ‘Cool Vendor 2016’

Aragon Research ‘Hot Vendor 2016’

IR was named by the world’s leading IT research and 
advisory company, Gartner as a Cool Vendor for our 
innovative and unique method to deliver visibility 
specifically into Microsoft Skype for Business voice calls, 
with readiness to provide the same insight for Microsoft 
Skype for Business Online.

Each year, Silicon Valley based analyst firm Aragon 
Research selects Hot Vendors across multiple markets 
that are doing something truly new or different. IR was 
selected for our ability to manage highly complex UC 
environments across multiple vendors, including Microsoft, 
Cisco and Avaya, without the use of network probes. 

Gartner “Cool Vendors in Availability and Performance, 
2016” by Cameron Haight, Vivek Bhalla, Colin Fletcher 
and Sanjit Ganguli, 19 April, 2016

Hot Vendors in Unified Communications and 
Collaboration, 2016

Research Note 2016‑24 
July 20, 2016

Our products, our promise

Prognosis for United 
Communications

Prognosis for 
Payments

Prognosis is the best 
experience management 
solution for unified 
communications on 
premises, as a hybrid or 
in the cloud.

We help our customers 
de‑risk deployments of 
new technology and 
help them realise the 
benefits from their 
investment sooner.

Prognosis for 
Contact Center

Prognosis ensures the 
quality of customer 
interactions across 
multiple channels like 
voice, video, web, app 
sharing and web chat.

It enables our customers 
to deliver the best user 
experience possible for 
collaboration, meetings, 
and voice/video calls 
across Microsoft Skype for 
Business, Cisco, and Avaya 
UC solutions. 

Prognosis performance 
management is specifically 
designed to give complete 
real‑time visibility into 
payments processors 
like ACI, FIS, other 
vendors and in‑house 
developed systems.

Specialist initiatives 
around call recording 
assurance, stress and 
heartbeat testing ensure 
compliance, performance 
under load and day to 
day functionality. 

Prognosis for 
Infrastructure

Prognosis IT infrastructure 
performance management 
spots patterns in data 
so customers can stop 
problems in their tracks.

This means they can 
make systems work better, 
respond to issues faster, 
prevent outages and get 
back to doing what they 
do best.

11

Integrated Research and its controlled entities Annual Report 20161212

Integrated Research and its controlled entities Annual Report 2016

Integrated Research and its controlled entities Annual Report 2016Directors’ 
Report

Contents

14  Review of operations
18  Outlook and strategy for 2017
20  Board of Directors
22  Senior management
24  Directors’ interests
25  Share options and performance rights
27  Remuneration report (audited)
29  Service agreements

Integrated Research and its controlled entities Annual Report 2016

13
13

Integrated Research and its controlled entities Annual Report 2016Directors’ 
Report

Annual revenue  20%

Unified Communications revenue  39%

Annual after tax profit  12%

$84.5M

$50.8M

$16.0M

Integrated Research has developed 
its Prognosis products around a 
fault‑tolerant, highly distributed 
software architecture, designed to 
achieve high levels of functionality, 
scalability and reliability with a low 
total cost of ownership. 

Integrated Research services 
customers in more than 50 countries 
through direct sales offices in the 
USA, UK, Germany, Singapore 
and Australia, and via a global, 
channel‑driven distribution 
network. Integrated Research’s 
customer base consists of many of 
the world’s largest organisations 
and includes major stock 
exchanges, banks, credit card 
companies, telecommunications 
companies, computer 
companies, service providers and 
manufacturing companies.

The Company generates its 
revenue from licence fees, 
recurring maintenance and 
consulting services. More recently, 
the Company added testing 
solution services revenue through 
the acquisition of the business 
of IQ Services. Revenue from 
the sale of licences where there 
is no post‑delivery obligations is 
recognised in profit at the date 
of the delivery of the licence 
key. Revenue from maintenance 
contracts is recognised rateably 
over the service agreement, which 
is typically one year. Revenue from 
consulting services and testing 
solution services is recognised over 
the period the services are delivered.

Review and 
results of 
operations

Overview

The Company achieved a 12% 
increase in annual after tax profit 
over the prior year to $16.0 million, 
which is within the guidance provided 
to the Australian Stock Exchange 
on July 20, 2016. The strong result 
was driven through licence sale 
growth in Unified Communications. 
The Company saw growth across 
European and Asia‑Pacific markets 
and saw triple‑digit growth in product 
sales on the Microsoft Skype for 
business platform. 

Revenue

Revenue for the year was 
$84.5 million, an increase of 
20% over 2015. Licence fees 
increased by 11% to $45.7 million 
with strong growth from Unified 
Communications partially offset 
with lower Infrastructure sales. 
Maintenance revenues grew 15% 
over the previous corresponding 
year despite a lower than historical 
average customer retention rate 
of 91%. Revenue from consulting 
services grew by 33% to $7.4 million. 
Revenue was enhanced by a stronger 
US dollar relative to the prior year. 
In constant currency, annual revenue 
increased by 10% compared to the 
prior year.

Review of 
operations and 
activities

Principal activities

Integrated Research Limited’s 
principal activities are the design, 
development, implementation and 
sale of systems and applications 
management computer software 
for business‑critical computing, 
Unified Communication networks 
and Payment networks. 

Group overview

Integrated Research has a 
twenty‑eight year heritage 
of providing performance 
monitoring, diagnostics 
and management software 
solutions for business‑critical 
computing environments. 

Since its establishment in 1988, 
the Company has provided its core 
Prognosis products to a cross section 
of large organisations requiring high 
levels of computing performance 
and reliability for mission critical 
business operations. 

The Prognosis product range is an 
integrated suite of monitoring and 
management software, designed to 
give an organisation’s management 
and technical personnel operational 
insight into and optimise the 
operation of their HP NonStop, 
distributed system servers, 
Unified Communications (“UC”), 
and Payment environments and the 
business applications that run on 
these platforms. 

14

Integrated Research and its controlled entities Annual Report 2016Directors’ ReportThe following table presents 
Company revenues for each of the 
relevant product groups:

In thousands of AUD

Unified Communications

Infrastructure

Payments

Consulting

Total revenue

Unified Communications (UC) 
revenue rose 39% over the previous 
year driven through an array of 
large software deals with customers 
including Cisco, Citigroup, Dell, Ford 
Motor Company, HSBC, Nationwide 
Building Society (UK) and T‑Systems. 
The Company achieved UC licence 
sales growth across all of the major 
UC platforms including Microsoft, 
Avaya and Cisco.

Infrastructure revenues decreased by 
10% over the previous year. After a 
strong above trend performance 
in HP Non‑Stop revenues in 2015, 
the high margin Infrastructure 
product line delivered $20.8 million 
in revenue for 2016 consistent with 
the previous five year average. 
The annual revenue from the 
Infrastructure product line is highly 
correlated to the underlying licence 
renewal profile. The 2017 renewal 
profile should assist in underpinning a 
steady performance for that year.

2015 % Change

2016

50,778

20,812

5,576

7,366

36,485

23,177

5,069

5,548

84,532

70,279

39%

(10%)

10%

33%

20%

Payments revenue rose 10% over the 
previous year with strong licence sale 
growth coming from the UK with a key 
deal with Barclaycard. The Company has 
expanded its suite of Payments products 
by adding new products for additional 
platforms, vendors and applications, 
including fraud management, payments 
analytics and wholesale money 
transfer applications.

Consulting services showed growth for 
a seventh year in a row, with revenue 
increasing 33% to $7.4 million as 
customers increasingly look to extend 
their Prognosis solution to provide 
greater insight into their Unified 
Communications, Payments and 
Infrastructure environments.

The following table presents 
Company revenues for each of the 
relevant geographic segments in 
underlying natural currencies:

Americas (USD’000)

Europe (£’000)

Asia Pacific (A$’000)

2016

41,997

8,438

10,271

2015 % Change

43,621

5,338

8,866

(4%)

58%

16%

The Americas strong performance in 
2015 was partly driven by a cyclical 
upswing in Infrastructure from 
HP‑NonStop renewals. The reduction 
of these renewals in 2016 dragged the 
overall Americas performance down 
to finish the year 4% below 2015. 
The Americas continues to be the 
largest revenue contributor for the 
group and the forward Infrastructure 
renewal pipeline shows a return to 
historic averages. The Americas 
performance for 2016 delivered a 
solid performance in the Unified 
Communications product line from 
both the traditional Avaya and Cisco 
platforms as well as the rapidly growing 
Microsoft Skype for Business platform. 

The Company’s strategic investments 
made in 2015 into Europe paid off in 
2016 with revenue growing by 58% to 
£8.4 million. The growth was across both 
the UK and Continental Europe with key 
wins in both Unified Communications 
and Payments. The key account wins 
included a handful of large deals such as 
Barclaycard, HSBC, Nationwide Building 
Society and T‑Systems.

The investment in the Singapore office 
and the sales team enabled Asia Pacific 
to grow revenue by 16% to $10.3 million. 
The licence growth was delivered 
across Infrastructure and Unified 
Communications products. 

15

Integrated Research and its controlled entities Annual Report 2016Expenses

The Company continued to focus on expanding its capabilities and improving productivity. Total expenses were 
$64.5 million, up 22% against the prior year. The increase in cost was driven by three factors. Firstly the annualisation of 
investments made part way through the 2015 financial year; secondly, additional cost carried from the acquisition of 
the Testing Solutions business; and thirdly, the higher cost base was driven through a lower Australian dollar giving rise to 
higher offshore translated costs. In constant currency, expenses were up 14%. The number of staff at the end of the current 
year was 231 (2015: 222). The following table presents the Company’s cost base compared to the preceding year:

In thousands of AUD

Research and development expenses

Sales, consulting and marketing expenses

General and administration expenses

Total expenses

2016

13,582

44,983

5,962

64,527

2015

12,431

35,161

5,220

52,812

Research and development expenditure of $13.6 million was 16% of total revenue. Prognosis 11 was released in June 2016 
and will provide the Company with further growth opportunities in coming periods. Product enhancements in Call 
Recording Assurance, Skype for Business and Unified Communications for service providers should see revenue 
realisation in the 2017 financial year and beyond. Development activities in Payments will enable visibility into new 
technology roll‑outs such as Apple Pay. In addition, the Company continues to maintain certification with all the major 
Unified Communications platforms, the only vendor to do so.  

Net research and development expenses are represented as follows:

In thousands of AUD

Gross research and development spending

Capitalisation of development expenses

Amortisation of capitalised expenses

Net research and development expenses

2016

14,007

(9,565)

9,140

13,582

2015

13,215

(9,037)

8,253

12,431

16

Integrated Research and its controlled entities Annual Report 2016Directors’ ReportShareholder 
returns

Returns to shareholders remain 
strong through the payment of 
partly franked dividends:

Net profit ($’000)

Basic EPS

Dividends per share

Dividend franking percentage

Return on equity

2016

2015

$16,029

$14,251

9.42¢

6.5¢

58%

39%

8.41¢

7.5¢

35%

39%

2014

$8,489

5.03¢

5.0¢

33%

28%

Financial 
position

The following table presents key 
items from the consolidated 
statement of financial position:

In thousands of AUD

Assets:

Cash and cash equivalents (current)

Trade and other receivables (current and non‑current)

Intangible assets (non‑current)

2016

2015

8,544

52,390

21,972

15,323

38,272

17,020

Liabilities:

Deferred revenue (current and non‑current)

25,946

22,523

Equity

41,046

36,132

The Company’s end of year cash 
position was $8.5 million, down 
44% compared to the prior year. 
The reduction in year end cash has 
been driven primarily by the change in 
customer buying patterns where there 
has been a greater take‑up of term 
based renewal contracts over perpetual 
upfront cash arrangements. Whilst this 
purchasing change has reduced cash 
in the short term, the increase in the 
term contract activity bodes well for the 
future as the renewal opportunities will 
provide a compounding revenue effect 
in future periods. The Company has 
completed two years of a three year 
transition and sees the 2018 financial 
year as the time when this revenue 
compounding will begin to take effect 
and as a result drive an improvement 
to both cashflow from operations as 
well as underpin revenue growth. In the 
short term, there is the possibility of 
working capital fluctuations and as a 
result, the Company has established 
a three year $10 million multicurrency 
debt facility to fund these fluctuations. 

During the year, $1.5 million was drawn 
down from the debt facility but was 
repaid before the end of the year. 
The Company remains free of debt as 
at 30 June 2016.

Trade and other receivables increased 
by 42% over the preceding year due to 
three factors. Firstly, a strong increase 
in sales toward the end of the year; 
secondly a weaker Australian dollar 
resulting in higher translated US 
dollar debtors; and thirdly an increase 
in deferred payment terms with 
customers who seek to make regular 
annual payments over the term of their 
committed contract. 

The increase in intangible assets arose 
primarily from the acquisition of the 
IQ Services business. 

The consolidated statement of financial 
position presented at page 47 together 
with the accompanying notes provides 
further details.

17

Integrated Research and its controlled entities Annual Report 2016Outlook and  
Strategy for 2017

Hundreds of thousands 
of businesses rely 
on billions of Unified 
Communications 
interactions everyday 
to run their business; 
IR Prognosis ensures the 
quality of experience 
and optimises these 
mission critical 
internal and external 
customer interactions. 

On the Payments side of the 
business hundreds of millions of 
people rely on billions of payments 
transactions daily, IR Prognosis oils 
the smooth operation of their daily 
lives and of the business economy 
that we all depend on. 

Prognosis derives its competitive 
advantage from its unique 
intellectual property (IP) and design 
that enables real time insight, 
monitoring, fault root cause analysis, 
business and operational analytics, 
performance management and 
optimisation. The solution is highly 
scalable, extremely flexible and 
delivers very deep visibility into the 
diversity of systems and applications 
that it manages. As such, Prognosis 
is ideally suited to complex, 
high transaction volume, mission 
critical and high traffic environments.

Competition exists in each of 
the markets in various forms. 
Firstly, some of the large telephony 
and payment vendors provide their 
own performance management 
software, although this is generally 
inferior to the capability of Prognosis 
and does not solve the problem 
where heterogeneous multi‑vendor 
environments exist, as is most often 
the case. Secondly, some of the 
large solution software vendors also 
provide performance management 

capabilities, but this is typically 
not their core specialisation. 
Lastly, the Company from time to 
time competes with smaller, start‑up 
niche vendors. The Company remains 
focused on sustaining its competitive 
advantage through continuing 
innovation that comes from its 
research and development program.

Through deep visibility, forensic 
analysis into the root cause of 
problems, extensive analytics 
at multiple levels and recently, 
new automation capabilities, 
Prognosis enables proactive 
and rapid resolution of issues, 
capacity management as well 
as operational, cost and user 
experience optimisation.

The solution provides insight 
into potential issues before 
they become business‑critical. 
Prognosis helps users improve 
their operational maturity by 
proactively minimising expensive 
outages, lowering costs, improving 
user satisfaction, retaining and 
growing customers and optimising 
IT operations and resources. 
Prognosis is progressively using its 
real time access to big data volumes 
to deliver insights into a customer’s 
business that goes beyond improving 
and optimising operational efficiency. 
Through real time access and 
analysis Prognosis Business Insights 
reveals business and customer 
trends that are leveraged for 
economic, fraud management and 
competitive advantage.

The Company’s growth strategy 
is to create, sell and support 
Prognosis‑based products and 
services that deliver profitable 
growth from existing markets and 
customers, as well as creating new 
products that open new markets.

The Company currently focuses on 
three core markets: Infrastructure, 
Communications and Payments. 
The Company is actively building a 

fourth core market in the Contact 
Centre space. While growth in the 
Contact Centre solutions has been 
strong, this has not yet become a 
material part of the business. 

The Infrastructure market for 
Integrated Research includes users 
of high‑end computing systems 
such as the HP NonStop platform 
for financial, telecommunication, 
trading, manufacturing and other 
high‑volume, high‑value mission 
critical transaction environments. 
NonStop is an important part of 
HP’s server strategy and remains 
at the operational core of many 
of the world’s largest companies. 
The Company continues to invest in 
Prognosis for Nonstop to be aligned 
with HP and its customers. Prognosis 
for Distributed Systems (Windows, 
Unix and Linux) is mostly sold 
alongside the Company’s NonStop 
and Unified Communications 
products as customers seek a 
common monitoring interface for all 
platforms, or convert applications 
from one platform to another.

The Communications segment 
includes users of IP Telephony 
and Unified Communications 
(UC) applications such as audio 
communication, video, messaging, 
collaboration, mobility and presence. 
The Company anticipates growth 
in this segment through the 
ongoing shipment of IP based video, 
telephony and other endpoints 
as well as the increasing value 
per endpoint through the use of 
UC applications. UC networks are 
becoming more pervasive, more 
mission critical and more complex 
and as such they require effective 
performance and user experience 
management. Prognosis is strongly 
positioned to benefit from this need. 
The company will continue to 
invest in R&D to expand the suite 
of Prognosis for UC products to 
cover more platforms, vendors 
and applications, and by doing so 
increase the Company’s addressable 
market and revenue potential. 

18

Integrated Research and its controlled entities Annual Report 2016Directors’ ReportIR has been a trusted Microsoft 
Unified Communications partner 
since 2010, helping customers and 
partners successfully plan, deploy, 
test, operate and optimize Skype for 
Business. In March 2016 IR Prognosis 
for Unified Communications 
completed certification as an IT 
Pro Tool certified solution for Skype 
for Business. Skype for Business IT 
Pro Tools partners help customers 
accelerate deployment and 
adoption of Skype for Business 
and migration from existing 
legacy communications systems. 
This ensures Microsoft customers can 
deliver the best possible experience 
for their users. Prognosis sales to 
customers using Skype for Business 
was a significant contributor to the 
growth in the Company’s Unified 
Communications product line 
and represents a major growth 
opportunity in the future. Microsoft 
Skype for Business is the fastest 
growing Unified Communications 
solution in the market today. 
Last month Prognosis was named as 
the only solution recommended by 
Microsoft for both the Essentials and 
Advanced category of their Skype 
Operations Framework, the best 
practices required for successful 
Skype for Business implementations. 

Prognosis has ensured voice and 
video quality and performance 
for Cisco Unified Communications 
solutions since 2000 and manages 
many of the largest and most 
complex Cisco implementations 
across the globe. Over the past year 
the Company has collaborated with 
Cisco to achieve compliance with 
both the US Government Federal 
Information Processing Standards 
(FIPS 140‑2) and the Federal Risk 
and Authorization Management 
Program (FedRAMP). 

The Company has expanded its suite 
of Payments solutions by adding new 
products for additional platforms, 
vendors and applications, including 
new technology for roll‑outs such 
as Apple Pay. This expands the 
company’s addressable market in 
the Payments segment and increases 
revenue potential. The Company 
will maintain this strategy in the 
Payments market. The strategic 
alliance with ACI, a global leader in 
the payments market, continues 
to support the Company’s 
Payments business. In FY2016 the 
Company expanded its leverage 

into the Payments market by 
growing relationships with additional 
payments software vendors 
including FIS (Efunds Corporation) in 
Asia Pacific. These new relationships 
are expected to deliver further 
growth over the coming years. 

IR Consulting Services provide 
Prognosis customers with 
implementation, customisation and 
training services to ensure that they 
get the most out of their investment 
in Prognosis. Consulting Services 
also help IR configure unique and 
repeatable solutions that extend the 
use and value of Prognosis. 

Consulting Services achieved 
growth in FY2016 for the seventh 
consecutive year. The Company 
will continue to invest in people and 
processes to grow consulting revenue 
and margin.

On 1 July 2015 IR completed the 
acquisition of US based IQ Services. 
The acquisition expands IR’s 
Prognosis product line to now include 
best in class Virtual Customer® 
testing capabilities. Automated Virtual 
Customers® behave like an army of 
secret shoppers that test Unified 
Communications and Contact Centre 
systems to ensure they deliver the 
high quality customer experience 
real customers expect and demand. 
Embedded into Prognosis, the cloud 
based end‑to‑end automated testing 
as a service becomes the markets 
only fully integrated proactive systems 
management and testing product 
solution for UC and contact centres. 
The acquisition provides IR with 
an expanded offering to new and 
existing customers with unique 
competitive advantage as well as 
geographic expansion opportunities 
for the acquired products into 
Europe and Asia, as IQ Services 
previously only operated in North 
America. The integration of the 
acquisition is substantially complete. 
Bookings growth in FY2016 driven 
by solution synergies is expected 
to continue in FY2017 realising 
the potential of the acquisition 
going forward. 

In FY2015 the Company started 
a three year transition to reduce 
the number of one‑off perpetual 
licence sales and correspondingly 
increase the number of recurring 
term licences. The Company has 

now completed two years of the 
three year transition from perpetual 
to recurring term arrangements. 
The Company has managed to show 
healthy growth through each of the 
first two bridging years despite the 
lower initial cash of recurring term 
arrangements. The three year term 
licences that were signed in FY2015 
are coming up for renewal in FY2018 
and the Company expects that will 
provide a platform for cashflow and 
revenue growth. 

Prognosis has proven to be a 
sticky solution in the past with 
historical renewal rates of above 
90%. To maximize the benefit 
of compounding recurring term 
renewals that will accelerate from 
FY2018 and beyond the Company 
will focus on activities that will secure 
those renewals. These activities will 
include account management focus 
to ensure customer adoption and 
satisfaction as well as expansion 
of share of wallet. Analysis of the 
Company’s customer base of over 
1,200 enterprise customers shows 
significant potential to expand 
the number of IR solutions sold 
to each customer. Prognosis is a 
modular solution and customers 
will typically purchase only a 
small subset of those modules on 
their initial purchase. Subsequent 
purchases may include additional 
solutions such as Reporting and 
Analytics, Video Management, 
Testing solutions, Contact Centre 
and Call Recording Assurance 
to name some of the most 
commonly applicable. These are sold 
at rates per user per year that vary 
between 12.5% to 300% of the initial 
purchase price. 

The Company has also proven its 
capability to acquire new customers, 
adding over 100 new logos in FY2016. 

The compounding impact of 
recurring term renewals, expansion 
of share of wallet and continued 
focus on new customer acquisition 
are three significant factors that 
management expects to support 
growth through FY2017 and beyond. 

The Company continues to invest in its 
R&D capability through the use of the 
Agile development methodology which 
has improved the rate and quality of 
software production for the Company.

19

Integrated Research and its controlled entities Annual Report 2016Directors

The directors of the Company at any time during or since the end of the financial year are listed below: 

Steve Killelea
AM 

Non‑Executive Director 
and Chairman

Darc Dencker‑
Rasmussen
MAICD
Managing Director and 
Chief Executive Officer

Nick Abrahams
B Comm, LLB (Hons), MFA

Alan Baxter
BSc, Dip Ed

Non‑Executive Director 

Independent 
Non‑Executive Director

Steve founded Integrated 
Research in August 1988 
and held the position of 
Managing Director and 
Chief Executive Officer until 
retiring from his executive 
position in November 2004. 
He was appointed as a 
Non‑Executive Director 
in November 2004 
and elected Chairman 
in July 2005. Steve is also 
Chairman of the Institute 
for Economics and Peace, 
Smarter Capital and 
The Charitable Foundation 
and for activities involved 
with these he has received 
a number of international 
awards including the Order 
of Australia, Luxembourg 
Peace Prize.  

Listed company directorships 
held in the past three years 
other than listed above: 
None.

Age: 67 years.

Darc was appointed 
CEO and Managing 
Director of Integrated 
Research in October, 
2013. Darc is a seasoned 
25‑year IT and enterprise 
software professional with 
extensive international 
experience in building and 
growing Software as a 
Service (SaaS) and Cloud 
based businesses. Darc was 
Chief Operating Officer 
and served as Executive 
Director at TrustedCloud 
(formerly IntraPower 
ASX:IPX). Prior to joining 
TrustedCloud, Mr Rasmussen 
served as Senior Vice 
President of CRM (Customer 
Relationship Management) 
at SAP in Germany and led 
SAP’s Strategic Initiative 
to build and grow their 
CRM business worldwide. 
Darc also served as Director 
and Vice President for 
Asia Pacific for Softbrands 
(acquired by Infor) and 
built their significant 
regional footprint. 

Listed company directorships 
held in the past three years 
other than listed above: 
None.

Age: 56 years.

Nick was appointed as a 
Director in September 2014. 
Mr. Abrahams is highly 
experienced in corporate, 
intellectual property 
and international law 
pertaining to the technology 
industry, with over 
20 years’ experience as 
a private practice lawyer. 
He has worked extensively 
internationally representing 
Australian high‑tech 
companies as well as working 
for three years with a law 
firm in Japan. Mr Abrahams 
also spent time working 
in the United States in 
the late nineties and was 
an executive with Warner 
Brothers in Los Angeles, 
followed by a period as a 
senior executive at listed 
technology company, Spike 
Networks, also in Los Angeles. 
Mr Abrahams returned 
to legal practice in 2002 
and is a partner of and 
leads the Asian technology 
practice of a global law firm. 
Nick’s current term will 
expire no later than the 
close of the 2017 Annual 
General Meeting. 

Listed company directorships 
held in the past three years 
other than listed above: 
None. 

Age: 50 years.

Alan was appointed as a 
Director in June 2009. 
Alan has over forty years’ 
experience in Information 
Technology covering 
a broad range of the 
industry’s activities. 
These include many 
years in a variety of 
roles with IBM Australia, 
CEO of DMR Consulting 
in Australia and COO of 
Fujitsu Consulting’s global 
operations from London. 
He was non‑executive 
Chairman of Fujitsu 
Australia & New Zealand, 
a director of Mincom Ltd, 
non‑executive Chairman 
of Konekt Limited and 
also of Innogence Limited. 
He is a non‑executive 
director of CPT Global, 
a publicly listed technology 
consulting company. 
Alan’s current term will 
expire no later than the 
close of the 2018 Annual 
General Meeting. 

Listed company directorships 
held in the past three years 
other than listed above: 
None. 

Age: 71 years.

20

Integrated Research and its controlled entities Annual Report 2016Directors’ ReportPaul Brandling
BSc Hons, MAICD

Independent 
Non‑Executive Director

Garry Dinnie
BCom, FCA, FAICD, FAIM, 
MIIA(Aust)

.
Independent 
Non‑Executive Director

Peter Lloyd
MAICD

Non‑Executive Director 

Company Secretary

David Purdue
BEc, MBA, Grad Dip CSP, 
FCA, FGIA, FCIS, GAICD

David was appointed 
Company Secretary 
in July 2012. David was 
also the Company’s Global 
Commercial Manager 
until his retirement 
in July 2016. Prior to this, 
David spent three years 
at Integrated Research’s 
Colorado office to manage 
the Americas finance 
operations. David is a 
Chartered Accountant and 
Chartered Secretary with 
over 25 years experience in 
both professional practice 
and industry.

Garry was appointed a 
Director in February 2013. 
He is a Director & Chair 
of the Audit & Risk 
Committee of CareFlight 
Limited, Australian 
Settlements Limited and 
a Director of a number 
of private companies. 
He is also the Chair or 
member of a number of 
Audit & Risk Committees 
of NSW public sector and 
private sector entities. 
He was previously a 
partner with Ernst & Young 
for 25 years specialising 
in audit, advisory and 
IT services. Garry’s current 
term will expire no later than 
the close of the 2016 Annual 
General Meeting. 

Listed company directorships 
held in the past three years 
other than listed above: 
Inabox Group Limited

Age: 64 years.

Peter was appointed director 
in July 2010. He has over 
40 years’ experience on 
computing technology, 
and in the sales and 
marketing of computer 
software products and 
services. For the past 
31 years, Peter has been 
specifically involved in the 
provision of payments 
solutions for banks and 
financial institutions. He is 
currently the proprietor of 
The Grayrock Group Pty Ltd, 
a management consultancy 
company focussing on 
the payments industry, 
and a Non‑Executive 
Director of Taggle Pty Ltd. 
Peter’s current term will 
expire no later than the 
close of the 2016 Annual 
General Meeting. 

Listed companies 
directorships held in the 
past three years: None.

Age: 62 years.

Paul was appointed a 
Director in August 2015. 
He worked in the information 
technology industry for 
28 years and has broad 
experience in hardware, 
services and software. 
He has previously held the 
positions of Vice President 
and Managing Director 
of Hewlett‑Packard South 
Pacific plus Vice President 
and Managing Director 
of Compaq South Pacific. 
From 2001 to 2012, 
Paul was a member of the 
International CEO Forum 
(Australia) and served as a 
Director of the Australian 
Information Industry 
Association (AIIA) from 
2002 to 2011. Mr Brandling 
was a Director of Amcom 
Telecommunications Limited 
until its acquisition and 
was a Director of Vocus 
Communications Limited 
until February 2016. He is 
currently a Director of cyber 
security specialist Tesserent 
Limited. Paul’s current term 
will expire no later than the 
close of the 2018 Annual 
General Meeting.

Listed company directorships 
held in the past three years 
other than listed above: 
None. 

Age: 58 years.

21

Integrated Research and its controlled entities Annual Report 2016Senior management

Peter Adams
B.Com, CA

Chief Financial Officer

Peter joined Integrated Research in March 2008 and is responsible 
for overseeing the Company’s finance and administration, 
including regulatory compliance and investor relations. Peter is a 
Chartered Accountant with over 25 years experience. He has held a 
number of senior accounting and finance roles, including seven years 
as CFO with Infomedia (an ASX‑listed technology company), six years 
with Renison Goldfields (ex ASX top 100 Resources Company) 
and two years with Transfield Pty Ltd. Peter’s career began with Arthur 
Andersen, where he was responsible for managing large audit clients.

Alex Baburin
B.App. Sc

Chief Operations Officer

Alex Baburin joined Integrated Research in November 2006 and 
is responsible for the Company’s software development and 
global support activities. Alex has over 25 years experience in 
the development, creation and management of high‑technology 
hardware and software products for Honeywell and Siemens. 
Before joining Integrated Research he was responsible for general 
management of the Siemens Access Control product line globally 
and for much of that time was based in Germany.

Jason Barker
BA (hons) 

Senior Vice President, 
Asia Pacific, Middle 
East & Africa

Jason joined IR in October 2014 and is responsible for all business 
operations across the Asia Pacific, Middle East & Africa regions. 
Jason joins with 20 years’ experience in Technology, 
Media & Telecommunications most recently as Vice President 
Sales, Asia Pacific at Acision where, based out of Singapore, he was 
responsible for leadership of the Sales team across the region. 
Prior to this Jason spent 5 years in Australia leading Asia Pacific 
teams with Subex and Surfkitchen and before this held several 
European focussed roles, based out of the UK.

Andre Cuenin
BSc, MBA

President Americas 
& VP European 
Field Operations

Andre joined Integrated Research in October 2008 and is 
responsible for all business operations in both the Americas 
and Europe region. Andre has over 25 years experience in 
IT sales, including VP of Field Operations at Stratavia, where he 
was responsible for sales and professional services marketing 
worldwide. Prior to this he spent 15 years with CA (previously known 
as Computer Associates) in several senior management positions 
including VP of Worldwide Sales Operations.

Heidi Newbery
BSc, PGDip Psych, 
GDip HR 

General Manager ‑ 
Human Resources

Heidi is responsible for the Human Resources and Learning 
Development functions which includes responsibility for 
aligning strategic HR initiatives with the Business Strategy 
that enable a high performance culture. Heidi has over 
18 years HR, sales and adult learning experience mostly within 
global organisations in the software and technology industry.

Kevin Ryder 
M.Mgt, MBA 

Chief Marketing Officer, 
Global Marketing

Kevin joined IR in October 2013 and as Chief Marketing Officer 
is responsible for product marketing, strategic alliances, 
partner programs and marketing communications. Kevin has over 
25 years sales and marketing experience in the ICT industry, including 
leadership roles in Europe, North America, Asia and Australia. 
Most recently he was the Enterprise Marketing Director at Microsoft 
and prior to that, GM of Marketing at KAZ Group (now owned 
by Fujitsu). Kevin was also GM for Eicon Technology and in that role 
was responsible for establishing the Asia Pacific regional office in 
Sydney and successfully growing the business.

22

Integrated Research and its controlled entities Annual Report 2016Directors’ ReportThe directors present their report together with the Financial Statements of Integrated Research Limited 
(“the consolidated entity”), being the Company and its controlled entities, for the year ended 30 June 2016 and the 
Auditor’s Report thereon. 

Results

The net profit of the consolidated entity for the 12 months ended 30 June 2016 after income tax expense was 
$16.0 million.

Dividends

Dividends paid or declared by the Company since the end of the 
previous financial year were:

Cents 
Per share

Final 2015 ‑ Ordinary shares

Interim 2016 ‑ Ordinary shares

Final 2016 ‑ Ordinary shares

35% franked

55% franked

60% franked

4.0

3.0

3.5

Total 
Amount 
$’000

6,793

5,113

5,970

Date of 
Payment

22 Sep 2015

20 Apr 2016

13 Oct 2016

Events subsequent to reporting date

For dividends declared after 30 June 2016 see Note 23 in the financial statements. The financial effect of dividends 
declared and paid after 30 June 2016 has not been brought to account in the financial statements for the year ended 
30 June 2016 and will be recognised in subsequent financial statements.

Future developments

Likely developments in the operations of the consolidated entity in future financial years and the expected results of 
those operations are referred to generally in the Review of Operations and Activities Report.

Further information on likely developments including expected results would in the Directors’ opinion, result in 
unreasonable prejudice to the Company and has therefore not been included in this Report.

Directors and company secretary

Details of current directors’ qualifications, experience, age and special responsibilities are set out on pages 20 to 21. 
Details of the company secretary and his qualifications are set out on page 21.

23

Integrated Research and its controlled entities Annual Report 2016 
Officers who were previously partners of the audit firm

No officers of the Company were partners of the current audit firm during the financial year.

Directors’ meetings

The numbers of meetings of the Company’s board of directors and of each board committee held during the year ended 
30 June 2016, and the numbers of meetings attended by each director were:

Board Meetings

Audit and Risk 
Committee Meetings

Nomination and 
Remuneration 
Committee Meetings

Strategy 
Committee Meetings

A

12

10

12

12

11

12

12

B

12

10

12

12

12

12

12

A

‑

5

8

8

3

‑

‑

B

‑

5

8

8

3

‑

‑

A

4

‑

‑

4

‑

4

‑

B

4

‑

‑

4

‑

4

‑

A

1

6

‑

‑

7

7

7

B

1

6

‑

‑

7

7

7

Alan Baxter

Paul Brandling

Nick Abrahams

Garry Dinnie

Peter Lloyd

Steve Killelea

Darc Rasmussen

A: Number of meetings attended.

B: Number of meetings held during the time the directors held office or was a member of the board or committee during the year.

State of affairs

In the opinion of the directors there were no significant changes in the state of affairs of the consolidated entity that 
occurred during the financial year under review.

Environmental regulation

The consolidated entity’s operations are not subject to significant environmental regulations under either 
Commonwealth or State legislation.

Directors’ interests

The relevant interest of each director in the shares, options or performance rights over ordinary shares issued by the 
companies in the consolidated entity and other relevant bodies corporate, as notified by the directors to the Australian 
Securities Exchange in accordance with S205G(1) of the Corporations Act 2001, at the date of this report is as follows:

Ordinary shares in Integrated Research

Options Performance rights

Directly held Beneficially held

Total

Number of options

Number of rights

Alan Baxter

Darc Rasmussen

Garry Dinnie

Steve Killelea

Nick Abrahams

Paul Brandling

Peter Lloyd

‑

279,273

‑

89,497,339

‑

10,202

‑

197,000

56,351

‑

337,612

2,000

‑

‑

197,000

335,624

‑

89,834,951

2,000

10,202

‑

‑

‑

‑

‑

‑

‑

‑

‑

250,000

‑

‑

‑

‑

‑

24

Integrated Research and its controlled entities Annual Report 2016Directors’ ReportShare options and performance rights

Options and performance rights granted to directors and senior executives

During or since the end of the financial year, the Company granted performance rights for no consideration over 
unissued ordinary shares in Integrated Research Limited to the following named directors and executive officers of the 
consolidated entity as part of their remuneration:

Directors

Darc Rasmussen

Executive Officers

Peter Adams

Alex Baburin

Jason Barker

Andre Cuenin

Kevin Ryder

Number of 
performance 
rights granted

Performance 
hurdle

Exercise price

Expiry date

250,000*

Yes

Nil

Oct 2016

25,000

15,000

30,000

85,000

15,000

Yes

Yes

Yes

Yes

Yes

Nil

Nil

Nil

Nil

Nil

 Mar 2019

 Mar 2019

Mar 2019

Mar 2019

 Mar 2019

The performance rights were granted under the Integrated Research Performance Rights and Option Plan 
(established November 2011). The Company will either issue shares or make an on‑market purchase for Mr Rasmussen 
upon his vesting conditions being satisfied.

*This is the third tranche of the original plan granted on 14 November 2013 of 850,000 rights. Tranche 1 and 2 of 
600,000 rights vested in October 2015.

Unissued shares under performance rights

Unissued ordinary shares of Integrated Research Limited under performance rights at the date of this report are as follows:

Expiry date

Oct 2016 

Oct 2016

Sep 2017

Sep 2017

Oct 2017

Sep 2018

Dec 2018

Mar 2019

Total performance rights

Performance rights

Exercise price

Number of shares

Nil 

Nil

Nil

Nil

Nil

Nil

Nil

Nil

150,000

250,000

465,000

85,000

700,000

93,800

60,000

195,000

1,998,800

Performance rights do not entitle the holder to participate in any share issue of the Company or any other body corporate.

25

Integrated Research and its controlled entities Annual Report 2016 • The non‑audit services provided 
do not undermine the general 
principles relating to auditor 
independence as set out in 
Professional Statement F1 
Professional independence, 
as they did not involve reviewing 
or auditing the auditor’s own 
work, acting in a management 
or decision making capacity 
for the Company, acting as an 
advocate for the Company or 
jointly sharing risks and rewards.

A copy of the auditors’ independence 
declaration as required under 
Section 307C of the Corporations Act 
is on page 82 and forms part of the 
Directors’ Report.

Rounding 
of amounts 
to nearest 
thousand dollars 

The Company is of a kind referred 
to in ASIC Corporations Instrument 
2016/191 and in accordance with 
that Class order, amounts in the 
Financial Statements and the 
Directors’ Report have been rounded 
off to the nearest thousand dollars, 
unless otherwise stated.

This report is made in accordance 
with a resolution of the directors.

Indemnification 
and insurance 
of officers 
and auditors

Indemnification

The Company has agreed to 
indemnify the directors of the 
Company on a full indemnity basis to 
the full extent permitted by law, for all 
losses or liabilities incurred by the 
director as an officer of the Company 
including, but not limited to, liability 
for negligence or for reasonable costs 
and expenses incurred, except where 
the liability arises out of conduct 
involving a lack of good faith.

To the extent permitted by law, 
the Company has agreed to 
indemnify its auditors, Ernst & Young 
Australia, as part of the terms of 
its audit engagement agreement 
against claims by third parties 
arising from the audit (for an 
unspecific amount). No payment has 
been made to Ernst & Young during 
or since the financial year.

Insurance

During the financial year Integrated 
Research Limited paid a premium to 
insure the directors and executive 
officers of the consolidated entity 
and related bodies corporate.

The liabilities insured include costs 
and expenses that may be incurred 
in defending civil or criminal 
proceedings that may be brought 
against officers in their capacity as 
officers of the consolidated entity.

Remuneration 
report

The Company’s Remuneration Report, 
which forms part of this Directors’ 
Report, is on pages 27 to 37.

Corporate 
governance

A statement describing the 
Company’s main corporate 
governance practices in place 
throughout the financial year is 
on pages 38 to 43.

Non‑audit 
services

During the year Ernst and Young, 
the Company’s auditor, has 
performed certain other services in 
addition to their statutory duties.

The board has considered the 
non‑audit services provided 
during the year by the auditor 
and in accordance with written 
advice provided by resolution of 
the Audit & Risk Committee, is 
satisfied that the provision of those 
non‑audit services during the year 
by the auditor is compatible with, 
and did not compromise, the auditor 
independence requirements of 
the Corporations Act 2001 for the 
following reasons:

 • All non‑audit services were subject 

to the corporate governance 
procedures adopted by the 
Company and have been reviewed 
by the Audit & Risk Committee 
to ensure they do not impact the 
integrity and objectivity of the 
auditor, and

Steve Killelea 
Chairman

Darc Rasmussen 
Chief Executive Officer

North Sydney, 22 August 2016

North Sydney, 22 August 2016

26

Integrated Research and its controlled entities Annual Report 2016Directors’ ReportRemuneration report 
(audited)

The financial performance objectives 
vary with position and responsibility 
and are aligned with each respective 
year’s budget. The non‑financial 
objectives vary with position and 
responsibility and include measures 
such as achieving strategic outcomes 
and staff development.

At the end of the financial year 
the Nomination and Remuneration 
Committee assesses the actual 
performance of the CEO against 
the KPIs set at the beginning of 
the financial year. A percentage 
of the predetermined maximum 
amounts for each KPI is awarded 
depending on results. The committee 
recommends the cash incentive to 
be paid to the CEO for approval by 
the board. 

Long‑term incentive

Prior to the 2012 financial year, 
options were issued to executive 
directors and other senior executives 
under the Employee Share 
Option Plan. In November 2011, 
the Company established a new 
plan titled Integrated Research 
Performance Rights and Options 
Plan (“IRPROP”). Performance rights 
are issued to executive directors 
and other senior executives under 
the IRPROP. The ability of executive 
directors to exercise either options 
or performance rights is conditional 
on the consolidated entity 
achieving certain profit after tax 
(PAT) performance hurdles over the 
vesting period. PAT was considered 
the most appropriate performance 
hurdle given its intrinsic link to 
creating shareholder wealth.

Remuneration 
policies 

Remuneration levels for key 
management personnel and 
secretaries of the Company, 
and relevant key management 
personnel of the consolidated 
entity are competitively set to 
attract and retain appropriately 
qualified and experienced 
directors and senior executives. 
The Nomination and Remuneration 
Committee obtains independent 
advice on the appropriateness 
of remuneration packages given 
trends in comparative companies 
both locally and internationally and 
the objectives of the Company’s 
remuneration strategy.

Key management personnel 
(including directors) have authority 
and responsibility for planning, 
directing and controlling the 
activities of the Company and the 
consolidated entity.

The remuneration structures 
explained below are designed to 
attract suitably qualified candidates, 
reward the achievement of strategic 
objectives, and achieve the broader 
outcome of creation of value for 
shareholders. The remuneration 
structure takes into account:

 • The capability and experience of 

the directors and senior executives

 • The directors and senior 

executives ability to control the 
relevant segment’s performance

 • The consolidated entity’s 
performance including:

 ‑ The consolidated 
entity’s earnings

 ‑ The growth in share price and 
returns on shareholder wealth

Remuneration packages include a mix 
of fixed and variable remuneration 
and short and long‑term performance 
based incentives.

Fixed remuneration 

Fixed remuneration consists of base 
remuneration (which is calculated 
on a total cost basis and includes 
any FBT charges related to employee 
benefits including motor vehicles), 
as well as employer contributions to 
superannuation funds.

Remuneration levels are reviewed 
annually through a process that 
considers individual, segment 
and overall performance of the 
consolidated entity. In addition, 
external remuneration surveys 
provide periodic analysis to ensure 
the directors’ and senior executives’ 
remuneration is competitive in the 
market place. A senior executive’s 
remuneration is also reviewed 
on promotion.

Performance‑linked 
remuneration 

Performance linked remuneration 
includes both short‑term and 
long‑term incentives and is designed 
to reward executive directors and 
senior executives for exceeding their 
financial and personal objectives. 
The short‑term incentive (STI) is an 
“at risk” bonus provided in the form 
of cash, while the long‑term incentive 
(LTI) is provided as either options or 
performance rights over ordinary 
shares of Integrated Research Limited 
under the rules of the share plans. 

Short‑term incentive bonus

The Nomination and Remuneration 
Committee is responsible for setting 
the key performance indicators 
(KPIs) for the Chief Executive Officer, 
and for approving the KPIs for the 
senior executives who report to him. 
The KPIs generally include measures 
relating to the consolidated entity, 
the relevant segment, and the 
individual, and include financial, 
people, customer, strategy and 
risk measures. The measures are 
chosen as they directly align the 
individual’s reward to the KPIs of 
the consolidated entity and to its 
strategy and performance.

27

Integrated Research and its controlled entities Annual Report 2016Consequences of performance on shareholder wealth 

In considering the consolidated entity’s performance and benefits for shareholder wealth, the Nomination and 
Remuneration Committee has regard to the following indices in respect of the current financial year and the previous 
four financial years:

New licences ($’000)

Net profit ($’000)

Dividends paid ($’000)

Closing share price

Change in share price

2016

45,725

16,029

11,906

$2.250

$0.560

2015

41,031

14,251

10,162

$1.690

$0.695

2014

2013

28,048

26,632

8,489

9,278

$0.995

($0.04)

9,078

8,413

$1.035

$0.37

2012

28,861

9,035

7,512

$0.665

$0.39

Net profit and new licence sales are considered in setting the STI, as two of the financial performance targets are profit 
after tax and new licences.

The Nomination and Remuneration Committee considers that the above performance linked structure is generating the 
desired outcomes. 

Key Management 
Personnel

The following were key management 
personnel of the consolidated entity 
at any time during the reporting period 
and unless otherwise indicated were 
key management personnel for the 
entire period:

Directors

Full year Steve Killelea

Chairman

Nick Abrahams

Alan Baxter

Peter Lloyd

Garry Dinnie

Darc Rasmussen Chief Executive Officer

Part year Paul Brandling

(Joined August 2015)

Other key management personnel

Full year Peter Adams

Chief Financial Officer

Alex Baburin

Chief Operations Officer

Jason Barker

Senior Vice President Asia Pacific

Andre Cuenin

President Americas & VP European Field Operations

Kevin Ryder

Chief Marketing Officer

David Purdue

Company Secretary

28

Integrated Research and its controlled entities Annual Report 2016Remuneration reportService agreements 

Service contracts for current executive directors and current senior executives 
are unlimited in term but capable of termination by either party according to 
a period specified in the employment contract and the consolidated entity 
retains the right to terminate the contract immediately by payment in lieu of 
notice or a severance payment or an amount for redundancy equal to the 
scale of payments prescribed in the NSW Employment Protection Act. 

Mr Darc Rasmussen, Chief 
Executive Officer, has a contract 
of employment with Integrated 
Research Limited dated 
26 August 2013, which provides 
for specific notice and severance 
undertakings of up to three 
months compensation depending 
on the particular circumstances. 
Mr Rasmussen can terminate his 
employment by giving three months 
prior notice in writing. 

Mr Andre Cuenin, President Americas 
& VP European Field Operations, 
has a contract of employment 
with Integrated Research Inc 
dated 22 September 2008, 
which provides for specific notice 
and severance undertakings of one 
month’s compensation depending 
on the particular circumstances. 
Mr Cuenin can terminate his 
employment by giving one month’s 
prior notice in writing.

Mr Peter Adams, Chief Financial 
Officer, has a contract of employment 
with Integrated Research Limited 
dated 23 January 2008, which 
provides for specific notice and 
severance undertakings of up to three 
months compensation depending 
on the particular circumstances. 
Mr Adams can terminate his 
employment by giving three months 
prior notice in writing. 

Mr David Purdue, Company Secretary 
and Global Commercial Manager, 
had a contract of employment 
with Integrated Research Limited 
dated 27 May 2008. Mr Purdue 
retired in July 2016 from the position 
of Global Commercial Manager. 
Mr Purdue continues in the role of 
Company Secretary.

Mr Alex Baburin, Chief Operations 
Officer, has a contract of employment 
with Integrated Research Limited 
dated 18 October 2006, which 
provides for specific notice and 
severance undertakings of up to one 
month’s compensation depending 
on the particular circumstances. 
Mr Baburin can terminate his 
employment by giving one month’s 
prior notice in writing.

Mr Kevin Ryder ‑ Chief Marketing 
Officer, Global Marketing, 
has a contract of employment 
with Integrated Research Limited 
dated 14 October 2013, which 
provides for specific notice and 
severance undertakings of one month 
compensation depending on the 
particular circumstances. Mr Ryder can 
terminate his employment by giving 
one month prior notice in writing.

Mr Jason Barker ‑ Vice President, 
APAC, has a contract of employment 
with Integrated Research Singapore 
Pte Limited dated 21 August 2014 
which provides for specific notice 
and severance undertakings of one 
month compensation depending 
on the particular circumstances. 
Mr Barker can terminate his 
employment by giving one month 
prior notice in writing.

29

Integrated Research and its controlled entities Annual Report 2016Non‑executive 
directors 

Total remuneration for all 
non‑executive directors last voted 
upon at the Annual General Meeting 
in November 2013 is not to exceed 
$750,000 per annum. 

Director’s base fees in FY2016 
were $70,000 per annum inclusive 
of compulsory superannuation. 
The chairman receives the base fee 
by a multiple of two. Director’s fees 
cover all main board activities and 
committee membership. Directors 
can elect to salary sacrifice their 
directors fees into superannuation.

Non‑executive directors do not 
receive performance related 
compensation or retirement benefits. 

Directors’ 
and executive 
officers’ 
remuneration 

Details of the nature and amount 
of each major element of the 
remuneration of each of the key 
management personnel director 
of the Company and each of the 
executives and relevant group 
key management executives are 
reported below.

The estimated value of options and 
performance rights disclosed is 
calculated at the date of grant using 
the Binomial option pricing model, 
adjusted to take into account the 
inability to exercise options during 
the vesting period. Further details 
of options and performance rights 
granted during the year are set 
out below.

“Executive officers” are officers who 
are involved in, or who take part 
in, the management of the affairs 
of Integrated Research Limited 
and/or related bodies corporate. 
Remuneration for overseas‑based 
employees has been translated to 
Australian dollars at the average 
exchange rates for the year.

No director or executive appointed 
during the year received a payment 
as part of his or her consideration for 
agreeing to hold the position.

30

Integrated Research and its controlled entities Annual Report 2016Remuneration reportShort term

2016
In AUD

Salary & 
fees
$

Bonus
$

Non‑
cash
benefits
$

Non‑executive Directors

Post‑ 
employ‑
ment

Super‑
annua‑
tion
contri‑
bution
$

Share‑
based 
pay‑
ments

Other 
compen‑
sation

Long 
term

Long 
service 
leave
$

Value of 
options 
and 
rights
$

Termina‑
tion
benefit
$

Proportion of 
remuneration

Perfor‑
mance 
related

Total
$

Value of 
options 
and 
rights

63,927

63,927

55,239

63,927

63,927

127,854

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

6,073

6,073

5,248

6,073

6,073

12,146

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

70,000

70,000

60,487

70,000

70,000

140,000

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

Nick Abrahams 

Alan Baxter

Paul Brandling 
(appointed  
August 2015)

Garry Dinnie

Peter Lloyd 

Steve Killelea 
(Chairman)

Executive 
Directors

Darc Rasmussen 

500,000 102,662

4,532

19,308

10,446 105,936

‑

742,884

14%

14%

Executive officers (excluding directors)

Peter Adams

291,797

49,385

4,532

19,308

6,086 40,842

Alex Baburin

278,953

27,410

Jason Barker 

346,535 210,662

‑

‑

23,104

32,572

5,651

37,718

Andre Cuenin

342,998 343,350

16,707

10,159

David Purdue 

199,613

15,000

4,532

19,308

3,976

16,904

Kevin Ryder 

244,242

48,013

380

31,380

5,402

27,716

‑

‑

38,707

23,774

‑

‑

‑

‑

‑

‑

411,950

382,304

619,008

736,988

259,333

357,133

12%

7%

34%

47%

6%

13%

10%

10%

6%

3%

6%

8%

Total compensation: 
key management 
(consolidated, 
including directors)

2,642,939 796,482

30,683 196,825

31,561 291,597

‑ 3,990,087

31

Integrated Research and its controlled entities Annual Report 2016 
Short term

2015
In AUD

Salary & 
fees
$

Bonus
$

Non‑
cash
benefits
$

Non‑executive Directors

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

50,158

63,927

13,277

63,927

63,927

127,854

23,276

Nick Abrahams 
(appointed 
September 2014)

Alan Baxter

Kate Costello 
(retired 
September 2014)

Garry Dinnie

Peter Lloyd 

Steve Killelea 
(Chairman)

Clyde McConaghy 
(retired 
November 2014)

Executive 
Directors

Post‑ 
employ‑
ment

Super‑
annua‑
tion
contri‑
bution
$

4,765

6,073

1,261

6,073

6,073

12,146

2,211

Share‑
based 
pay‑
ments

Other 
compen‑
sation

Long 
term

Long 
service 
leave
$

Value of 
options 
and 
rights
$

Termina‑
tion
benefit
$

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

Darc Rasmussen 

500,000 162,000

4,532

18,783

15,201 280,619

Executive officers (excluding directors)

Peter Adams

281,519

62,863

4,532

18,783

Alex Baburin

272,965

42,728

Jason Barker 
(appointed 
October 2014)

233,182

129,973

‑

‑

27,408

15,818

Andre Cuenin

292,143

370,449

13,886

8,764

8,156

7,610

‑

‑

27,109

27,109

17,826

54,828

David Purdue 

201,685

‑

4,532

18,783

4,991

15,081

Kevin Ryder 

225,473

34,478

5,408

‑

‑

‑

24,343

6,306

13,463

‑

‑

‑

Proportion of 
remuneration

Perfor‑
mance 
related

Value of 
options 
and 
rights

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

Total
$

54,923

70,000

14,538

70,000

70,000

140,000

25,487

981,135

17%

29%

402,962

377,820

396,799

16%

11%

33%

740,070

50%

245,072

304,063

5,408

‑

11%

‑

7%

7%

4%

7%

6%

4%

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

2,418,721 802,491

27,482

171,284

42,264 436,035

‑ 3,898,277

Jonathan 
Stern (resigned 
July 2014)

Total compensation: 
key management 
(consolidated, 
including directors)

32

Integrated Research and its controlled entities Annual Report 2016Remuneration report 
Analysis 
of bonuses 
included in 
remuneration 

Details of the vesting profile of the 
short‑term incentive cash bonuses 
awarded as remuneration to each 
director of the Company and each 
of the named Company executives 
and relevant group executives are 
detailed in this table:

Directors

Darc Rasmussen

Executives

Peter Adams

Alex Baburin

Jason Barker

Andre Cuenin

David Purdue

Kevin Ryder

Short term incentive bonuses

Included in 
remuneration
$ (A)

% vested in 
year

% forfeited in 
year 
(B)

102,662

41%

59%

49,385

27,410

210,662

343,350

15,000

48,013

77%

53%

99%

77%

100%

74%

23%

47%

1%

23%

‑

26%

(A) Amounts included in remuneration for the financial year represents 
the amount that vested in the financial year based on achievement 
of personal goals and satisfaction of specified performance criteria. 
No amounts vest in future financial years in respect of the short‑term 
incentive bonus scheme for the 2016 financial year.

(B)  The amounts forfeited are due to the performance or service criteria not 

being met in relation to the current financial year.

33

Integrated Research and its controlled entities Annual Report 2016Equity instruments 

All options refer to options over ordinary shares of Integrated Research Limited, which are exercisable on a one‑for‑one 
basis under the Employee Share Option Plan (ESOP).

Options and rights over equity instruments granted as compensation

No options have been granted to named executives either during or since the end of the financial year. Performance 
rights granted as compensation are listed in the table below.

Analysis of rights over equity instruments granted as compensation

Performance 
rights granted

Value yet to vest ($)

 Number

Date

Percent 
vested in 
year

Percent 
forfeited in 
year (A)

Financial 
year in 
which grant 
expires

Min
(B)

Directors

Darc Rasmussen

Executives

Peter Adams

Alex Baburin

Jason Barker

Andre Cuenin

David Purdue

Kevin Ryder

350,000

250,000

250,000

30,000

100,000

25,000

30,000

100,000

15,000

40,000

60,000

30,000

50,000

85,000

100,000

85,000

20,000

50,000

75,000

15,000

Nov‑13

Oct‑14

Oct‑15

Oct‑12

Nov‑14

Dec‑15

Oct‑12

Nov‑14

Dec‑15

Nov‑14

Nov‑14

Dec‑15

Oct‑12

Apr‑14

Nov‑14

Dec‑15

Oct‑12

Nov‑14

Nov‑14

Dec‑15

100%

100%

‑

100%

‑

‑

100%

‑

‑

‑

‑

‑

100%

‑

‑

‑

100%

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

2017

2017

2017

2016

2018

2020

2016

2018

2020

2018

2019

2020

2016

2018

2018

2020

2016

2018

2018

2020

‑

‑

nil

‑

nil

nil

‑

nil

nil

nil

nil

nil

‑

nil

nil

nil

‑

nil

nil

nil

Max
(C)

‑

‑

216,875

‑

84,470

46,147

‑

84,470

27,688

33,788

46,494

55,377

‑

79,639

84,470

156,901

‑

42,235

63,353

27,688

(A) The percentage forfeited in the year represents the reduction from the maximum number of options available to vest 

due to the performance hurdles not being achieved or due to the resignation of the executive.

(B)  The minimum value of performance rights yet to vest is $nil as the executives may not achieve the required 

performance hurdles or may terminate their employment prior to vesting. 

(C) The maximum values presented above are based on the values calculated using the Binomial option pricing model as 

applied in estimating the value of performance rights for employee benefit expense purposes.

34

Integrated Research and its controlled entities Annual Report 2016Remuneration reportOther transactions with key management personnel

Apart from the details disclosed in this note, no director has entered into a material contract with the consolidated entity 
since the end of the previous financial year and there were no material contracts involving directors’ interests existing at 
year‑end. 

Equity instruments

All performance rights refer to performance rights over ordinary shares of Integrated Research Limited, which are 
exercisable on a one‑for‑one basis under the Integrated Research Performance Rights and Option Plan (IRPROP).

Key management 
personnel 
compensation

The key management personnel 
compensation are as follows:

In AUD

Short‑term benefits

Post‑employment benefits

Long term benefit

Equity compensation benefits

Consolidated

2016

2015

3,470,104

3,248,694

196,825

31,561

171,284

42,264

291,597

436,035

3,990,087

3,898,277

35

Integrated Research and its controlled entities Annual Report 2016Performance rights over equity instruments granted 
as compensation

The movement during the reporting year in the number of performance rights over ordinary shares in Integrated 
Research Limited held, directly, indirectly or beneficially, by each key management person, including their related parties, 
is as follows:

Held at 
1 July
2015

Granted as 
compensation

Exercised

Other 
changes*

Held at
30 June
2016

Vested 
during the 
year

Vested and 
exercised 
at 30 June 
2016

Current Year

Directors

Darc Rasmussen

600,000

250,000 (600,000)

130,000

130,000

100,000

235,000

70,000

75,000

25,000

(30,000)

15,000

(30,000)

30,000

‑

85,000

(50,000)

‑

(20,000)

15,000

‑

‑

‑

‑

‑

‑

‑

‑

250,000

600,000

600,000

125,000

30,000

30,000

115,000

30,000

30,000

130,000

‑

‑

270,000

50,000

50,000

50,000

20,000

20,000

90,000

‑

‑

Darc Rasmussen

350,000

250,000

Held at 
1 July
2014

Granted as 
compensation

Exercised

Other 
changes*

Held at
30 June
2015

Vested 
during the 
year

Vested and 
exercised 
at 30 June 
2015

‑

‑

‑

‑

‑

30,000

30,000

100,000

100,000

‑

100,000

135,000

100,000

34,500

50,000

(14,500)

‑

75,000

‑

‑

‑

‑

‑

‑

‑

‑

600,000

130,000

130,000

100,000

235,000

70,000

75,000

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

14,500

14,500

‑

‑

Executives

Peter Adams

Alex Baburin

Jason Barker

Andre Cuenin

David Purdue

Kevin Ryder

Prior Year

Directors

Executives

Peter Adams

Alex Baburin

Jason Barker

Andre Cuenin

David Purdue

Kevin Ryder

* Other changes represent performance rights that expired or were forfeited during the year

Performance rights expire on the earlier of their expiry date or termination of the individual’s employment. 
No performance rights have been granted since the end of the financial year. The performance rights were provided at 
no cost to the recipients.

36

Integrated Research and its controlled entities Annual Report 2016Remuneration reportMovements in shares

The movement during the reporting period in the number of ordinary shares in Integrated Research Limited held, directly, 
indirectly or beneficially, by each key management person, including their related parties, is as follows:

Current Year

Non‑executive Directors

Nick Abrahams

Alan Baxter

Paul Brandling

Steve Killelea

Executive Directors

Darc Rasmussen

Executive officers 
(excluding directors)

Peter Adams

Alex Baburin

Andre Cuenin

David Purdue

Prior Year

Non‑executive Directors

Alan Baxter

Kate Costello

Steve Killelea

Executive Directors

Darc Rasmussen

Executive officers 
(excluding directors)

Peter Adams

Alex Baburin

David Purdue

Held at
1 July 2015

Purchases

Received on 
exercise of 
performance 
rights

Other 
changes*

Sales

Held at
30 June 
2016

‑

2,000

197,000

‑

10,202

94,834,951

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

2,000

197,000

10,202

‑ (5,000,000)

89,834,951

(320,727)

335,624

38,700

17,651

600,000

5,000

10,000

‑

33,250

‑

‑

‑

‑

30,000

30,000

50,000

20,000

‑

‑

‑

‑

‑

(15,000)

‑

‑

‑

Held at
1 July 2014

Purchases

Received on 
exercise of 
options

Other 
changes*

Sales

20,000

40,000

50,000

53,250

Held at
30 June 
2015

197,000

199,622

94,834,951

‑

‑

‑

8,700

30,000

5,000

10,000

18,750

‑

‑

‑

‑

‑

‑

‑

‑

‑

14,500

‑

(199,622)

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

197,000

‑

94,834,951

38,700

5,000

10,000

33,250

* Other changes represent net movement from ceasing to hold office.

Shareholdings at the date of the Directors’ Report for existing Key Management Personnel remain unchanged.

Other transactions with the consolidated entity

There were no other transactions between the key management personnel, or their personally‑related entities, and the 
consolidated entity.

37

Integrated Research and its controlled entities Annual Report 2016Corporate 
Governance 
Statement

This statement outlines 
the main corporate 
governance practices 
that were in place 
throughout the financial 
year, which comply 
with the ASX Corporate 
Governance Council 
recommendations, 
unless otherwise stated.

Board of 
directors and its 
committees

The full board currently holds twelve 
scheduled meetings each year and 
any extraordinary meetings at such 
other times as may be necessary to 
address any specific matters that 
may arise.

The agenda for its meetings is 
prepared in conjunction with 
the chairman, chief executive 
officer and company secretary. 
Standing items include strategic 
matters for discussion, the 
CEO’s report, financial reports, 
key performance indicator reports 
and presentations by key executives 
and external industry experts. 
Board papers are circulated in 
advance. Directors have other 
opportunities, including visits to 
operations, for contact with a wider 
group of employees.

Director education

The consolidated entity follows 
an induction process to educate 
new directors about the nature 
of the business, current issues, 
the corporate strategy and 
expectations of the consolidated 
entity concerning performance of 
directors. In addition executives make 
regular presentations to the board to 
ensure its familiarity with operational 
matters. Directors are expected to 
access external continuing education 
opportunities to update and enhance 
their skills and knowledge.

Role of the board

The board’s primary role is the 
protection and enhancement of 
long‑term shareholder value. 

To fulfil this role, the board is 
responsible for the overall corporate 
governance of the consolidated 
entity including evaluating and 
approving its strategic direction, 
approving and monitoring capital 
expenditure, setting remuneration, 
appointing, removing and creating 
succession policies for directors 
and senior executives, establishing 
and monitoring the achievement of 
management goals and assessing 
the integrity of internal control and 
management information systems. 
It is also responsible for approving 
and monitoring financial and 
other reporting. 

Board process

To assist in the execution of its 
responsibilities, the Board has 
established a number of board 
committees including a Nomination 
and Remuneration Committee, 
an Audit and Risk Committee 
and a Strategy Committee. 
These committees have written 
mandates and operating procedures, 
which are reviewed on a regular 
basis. The board has also established 
a framework for the management 
of the consolidated entity including 
board‑endorsed policies, a system 
of internal control, a business 
risk management process and 
the establishment of appropriate 
ethical standards.

38

Integrated Research and its controlled entities Annual Report 2016Corporate GovernanceIndependent advice and access 
to company information

Each director has the right of 
access to all relevant company 
information and to the company’s 
executives and, subject to prior 
consultation with the chairman, 
may seek independent professional 
advice from a suitably qualified 
adviser at the consolidated 
entity’s expense. A copy of the 
advice received by the director is 
made available to all other members 
of the board.

Composition of the board

The names of the directors of the 
company in office at the date of this 
report are set out on pages 20 to 21 
of this report.

The company’s constitution 
provides for the board to consist of 
between three and twelve members. 
At 30 June 2016 the board members 
were comprised as follows:

 • Mr Steve Killelea ‑ 

Non Executive Director (Chairman)

 • Mr Nick Abrahams ‑ 

Non Executive Director

 • Mr Alan Baxter ‑ Independent 

Non Executive Director

 • Mr Paul Brandling‑ Independent 

Non Executive Director

 • Mr Garry Dinnie ‑ Independent 

Non Executive Director

 • Mr Peter Lloyd ‑ 

Non Executive Director

 • Mr Darc Rasmussen ‑ Executive 

Director (Chief Executive Officer)

The election of Mr Killelea, who holds 
a majority of the company’s 
issued shares, as non‑executive 
chairman, does not comply with 
the ASX Corporate Governance 
Council recommendation that 
the chairman be an independent 
director. However, the board is 
satisfied that the company benefits 
from Mr Killelea’s experience and 
knowledge gained through his 
long involvement with Integrated 
Research and his associations 
throughout the information 
technology industry. Mr Killelea 
founded Integrated Research in 1988 
and was the CEO and managing 
director of the company until his 
retirement in November 2004. 

Mr Abrahams was appointed 
as a Non‑Executive Director 
in September 2014. While there are 
good arguments that Mr Abrahams 
is in fact independent, he has 
been classified as not independent 
due to a pre‑existing business 
relationship between Mr Abrahams 
and Mr Killelea. The board is satisfied 
that the company benefits from 
Mr Abrahams’ experience and 
knowledge gained through his more 
than 20 year career as a lawyer 
assisting technology companies in 
Australia and overseas.

At each Annual General Meeting 
one‑third of directors, any director 
who has held office for three years 
and any director appointed by 
directors in the preceding year 
must retire, then being eligible for 
re‑election. The CEO is not required 
to retire by rotation.

The composition of the board is 
reviewed on a regular basis to 
ensure that the board has the 
appropriate mix of expertise and 
experience. When a vacancy exists, 
through whatever cause, or where 
it is considered that the board 
would benefit from the services of 
a new director with particular skills, 
the Nomination and Remuneration 
Committee, in conjunction with 
the board, determines the selection 
criteria for the position based 
on the skills deemed necessary 
for the board to best carry 
out its responsibilities. The committee 
then selects a panel of candidates 
and the board appoints the most 
suitable candidate who must stand 
for election at the next general 
meeting of shareholders. 

The composition of the board during 
the year ended 30 June 2016 
did not comply with the ASX 
Corporate Governance Council 
recommendation that the majority 
of the board should be independent 
directors. However, the Company 
is working toward compliance 
through the appointment of Mr. Paul 
Brandling who is an Independent 
Non‑Executive Director.

The company secretary is 
accountable directly to the board, 
through the chair, on all matters to 
do with the proper functioning of 
the board.

39

Integrated Research and its controlled entities Annual Report 2016Nomination and 
Remuneration Committee

Responsibilities regarding 
nomination 

The Nomination and Remuneration 
Committee has a documented 
charter, approved by the board. 
The Nomination and Remuneration 
Committee is a committee of the 
board of directors and is empowered 
by the board to assist it in fulfilling 
its duties to shareholders and 
other stakeholders. In general, the 
committee has responsibility to: 1) 
ensure the company has appropriate 
remuneration policies designed to 
meet the needs of the company and 
to enhance corporate and individual 
performance and 2) review board 
performance, select and recommend 
new directors to the board and 
implement actions for the retirement 
and re‑election of directors.

Responsibilities regarding 
remuneration 

The Committee reviews and makes 
recommendations to the board on:

 • The appointment, remuneration, 

performance objectives 
and evaluation of the chief 
executive officer.

 • The remuneration packages for 

senior executives.

 • The Company’s recruitment, 
retention and termination 
policies and procedures for 
senior executives.

 • Executive remuneration and 

incentive policies.

 • Policies on employee incentive 

plans, including equity 
incentive plans.

 • Superannuation arrangements.

 • The remuneration framework and 
policy for non‑executive directors.

 • Remuneration levels are 

competitively set to attract and 
retain the most qualified and 
experienced directors and senior 
executives. The Remuneration 
Committee obtains independent 
advice on the appropriateness 
of remuneration packages, 
given trends in comparative 
companies and industry surveys. 
Remuneration packages include 
a mix of fixed remuneration, 
performance‑based remuneration 
and equity‑based remuneration.

The Committee develops and makes 
recommendations to the board on:

 • The CEO and senior executive 

succession planning.

 • The range of skills, experience 
and expertise needed on the 
board and the identification of 
the particular skills, experience 
and expertise that will best 
complement board effectiveness. 

 • A plan for identifying, reviewing, 

assessing and enhancing 
director competencies.

 • Board succession plans to 

maintain a balance of skills, 
experience and expertise on 
the board.

 • Evaluation of the 

board’s performance.

 • Appointment and removal 

of directors. 

 • Appropriate composition 

of committees. 

The terms and conditions of the 
appointment of non‑executive 
directors are set out in a 
letter of appointment, including 
expectations for attendance and 
preparation for all board meetings, 
expected time commitments, 
procedures when dealing with 
conflicts of interest, and the 
availability of independent 
professional advice.

The performance of the chief 
executive officer and the board 
was undertaken in the reporting 
period identifying both strengths 
and development actions. 
The performance of other senior 
management was conducted by 
the chief executive officer.

The members of the Nomination and 
Remuneration Committee during the 
year were:

 • Mr Alan Baxter ‑ Independent 
Non‑Executive (Chairman)

 • Mr Garry Dinnie ‑ Independent 

Non‑Executive Director

 • Mr Steve Killelea ‑ Non‑Executive

A matrix of skills and diversity 
of the board as required by 
the ASX corporate governance 
recommendations is available on the 
Company’s website at www.ir.com.

The Nomination and Remuneration 
Committee meets at least twice a 
year and as required. The Committee 
met four times during the year 
under review.

Audit and Risk Committee

The Audit and Risk Committee has 
a documented charter, approved by 
the board. The charter states that 
all members must be non‑executive 
directors with a majority being 
independent. The chairman may 
not be the chairman of the board. 
The committee advises on the 
establishment and maintenance of 
a framework of risk management 
and internal control of the 
consolidated entity. 

The members of the Audit and Risk 
Committee during the year were:

 • Mr Nick Abrahams ‑ 

Non‑Executive Director

 • Mr Garry Dinnie ‑ Independent 
Non‑Executive (Chairman) 

 • Mr Peter Lloyd ‑ Non‑Executive 

(up to November 2015)

 • Mr Paul Brandling‑ Independent 

Non Executive Director 
(from December 2015)

While the Committee is chaired by 
an independent director who is not 
chair of the Board, during first five 
months of the year the number 
of independent directors did not 
form a majority of the Audit and 
Risk Committee as recommended 
by the ASX Corporate Governance 
recommendations. In December 2015, 
the Company moved toward 
compliance on this matter with 
the appointment of Paul Branding 
(Independent Non‑Executive Director) 
to the Committee.

During the year, the Audit and Risk 
Committee provided the Board 
with updates to the Company’s risk 
management register (with the Board 
approving this document). 

40

Integrated Research and its controlled entities Annual Report 2016Corporate Governance • Monitor corporate risk 

management and assessment 
processes, and the identification 
and management of strategic and 
operational risks. 

 • Enquire of the auditors of 

any difficulties encountered 
during the audit, including any 
restrictions on the scope of their 
work, access to information or 
changes to the planned scope 
of the audit. 

The Audit and Risk Committee 
reviews the performance of the 
external auditors on an annual basis 
and normally meets with them during 
the year as follows:

Strategy Committee 

The Strategy Committee has a 
documented charter, approved 
by the board and is responsible 
for reviewing strategy and 
recommending strategies to 
the board to enhance the 
company’s long‑term performance. 
The committee is comprised of at 
least three members, including the 
chairman of the board and the 
Chief Executive Officer. The board 
appoints a member of the 
committee to be chairman.

The members of the Strategy 
Committee during the year were:

 • Mr Steve Killelea (Chairman) ‑ 

 • To discuss the external audit 

Non‑Executive

plans, identifying any significant 
changes in structure, operations, 
internal controls or accounting 
policies likely to impact the 
financial statements and to review 
the fees proposed for the audit 
work to be performed.

 • Prior to announcement of results:

 ‑ To review the half‑year and 
preliminary final report 
prior to lodgement with the 
ASX, and any significant 
adjustments required as a 
result of the auditor’s findings.

 ‑ To recommend the Board 

 • Mr Darc Rasmussen ‑ Executive

 • Mr Alan Baxter ‑ 

Independent Non‑Executive 
(up to October 2015)

 • Mr Peter Lloyd ‑ Non‑Executive

 • Mr Paul Brandling‑ 

Independent Non‑Executive 
(from November 2015)

The Strategy Committee is 
responsible for:

 • Review and assist in defining 

current strategy.

approval of these documents.

 • Assess new strategic opportunities, 

 ‑ Review the results and findings 
of the auditor, the adequacy 
of accounting and financial 
controls, and to monitor 
the implementation of any 
recommendations made.

 • To finalise half‑year and 

annual reporting:

 ‑ Review the draft financial 

report and recommend board 
approval of the financial report.

 • As required, to organise, review 

and report on any special 
reviews or investigations deemed 
necessary by the board.

including M&A proposals and 
intellectual property developments 
or acquisitions.

 • Stay close to the business 
challenges and monitor 
operational implementation 
of strategic plans.

 • Endorse strategy and business 
cases for consideration by the 
full board.

The Committee met seven times 
during the year under review.

The external auditor, Chief Executive 
Officer and Chief Financial 
Officer are invited to Audit and 
Risk Committee meetings at 
the discretion of the committee. 
The committee met eight times 
during the year and committee 
members’ attendance record is 
disclosed in the table of directors’ 
meetings on page 24.

The external auditor met with 
the audit committee/board eight 
times during the year, two of which 
included time without the presence 
of executive management. The Chief 
Executive Officer and the Chief 
Financial Officer declared in writing 
to the board that the company’s 
financial reports for the year 
ended 30 June 2016 comply with 
accounting standards and present 
a true and fair view, in all material 
respects, of the company’s financial 
condition and operational results. 
This statement is required annually.

The main responsibilities of the Audit 
and Risk Committee as set out in the 
charter include:

 • Serve as an independent 

party to monitor the financial 
reporting process and internal 
control systems. 

 • Review the performance 
and independence of the 
external auditors and make 
recommendations to the board 
regarding the appointment or 
termination of the auditors. 

 • Review the scope and cost of the 
annual audit, negotiating and 
recommending the fee for the 
annual audit to the board. 

 • Review the external auditor’s 

management letter and responses 
by management. 

 • Provide an avenue of 

communication between the 
auditors, management and 
the board. 

 • Monitor compliance with all 

financial statutory requirements 
and regulations. 

 • Review financial reports and other 
financial information distributed to 
shareholders so that they provide 
an accurate reflection of the 
financial health of the company. 

41

Integrated Research and its controlled entities Annual Report 2016Risk 
management

Under the Audit and Risk Charter, 
the Audit and Risk Committee 
reviews the status of business 
risks to the consolidated 
entity through integrated risk 
management programs ensuring 
risks are identified, assessed 
and appropriately managed and 
communicated to the board. 
Major business risks arise from such 
matters as actions by competitors, 
government policy changes and the 
impact of exchange rate movements.

Comprehensive policies and 
procedures are established such that:

 • Capital expenditure above 
a certain size requires 
board approval.

 •

Financial exposures are controlled, 
including the use of forward 
exchange contracts.

 • Risks are identified and managed, 
including internal audit, privacy, 
insurances, business continuity 
and compliance.

 • Business transactions are properly 

authorised and executed.

The Chief Executive Officer and 
the Chief Financial Officer have 
declared, in writing to the board 
that the Company’s financial reports 
are founded on a sound system 
of risk management and internal 
compliance and control which 
implements the policies adopted by 
the board.

Internal control framework

Conflict of interest

Each Director must keep the 
board advised, on an ongoing basis, 
of any interest that could potentially 
conflict with those of the Company. 
Where the board considers that a 
significant conflict exists the director 
concerned does not receive the 
relevant board papers and is not 
present at the meeting whilst the 
item is considered. The board has 
developed procedures to assist 
directors to disclose potential 
conflicts of interest. Details of director 
related entity transactions with the 
consolidated entity are set out in 
Remuneration report page 27 to 37.

Code of conduct

The consolidated entity has advised 
each director, manager and 
employee that they must comply 
with the code of conduct. The code 
aligns behaviour of the board and 
management with the code of 
conduct by maintaining appropriate 
core values and objectives. It may be 
reviewed on the company’s website 
and includes: 

 • Responsibility to the community 
and fellow employees to act 
with honesty and integrity, 
and without prejudice.

 • Compliance with laws and 

regulations in all areas where 
the company operates, including 
employment opportunity, 
occupational health and safety, 
trade practices, fair dealing, 
privacy, drugs and alcohol, and 
the environment.

 • Dealing honestly with customers, 

suppliers and consultants.

 • Ensuring reports and other 
information are accurate 
and timely.

 • Proper use of company resources, 
avoidance of conflicts of interest 
and use of confidential or 
proprietary information.

The board is responsible for the 
overall internal control framework, 
but recognises that no cost effective 
internal control system will preclude 
all errors and irregularities. The board 
has instigated the following internal 
control framework:

 •

Financial reporting ‑ Monthly 
actual results are reported against 
budgets approved by the directors 
and revised forecasts for the year 
are prepared monthly.

 • Continuous disclosure ‑ Identify 

matters that may have a 
material effect on the price of the 
Company’s securities, notify them 
to the ASX and post them to the 
Company’s website. 

 • Quality and integrity of personnel 
‑ Formal appraisals are conducted 
at least annually for all employees.

 •

Investment appraisals ‑ Guidelines 
for capital expenditure include 
annual budgets, detailed appraisal 
and review procedures and levels 
of authority.

Internal audit

The Company does not have an 
internal audit function but utilises 
its financial resources as needed 
to assist the board in ensuring 
compliance with internal controls.

Material exposure to 
economic, environmental and 
social sustainability risks

By the nature of the industry that the 
Company participates in, exposures 
to economic, environmental and 
social sustainability risks are not 
considered material.

Ethical 
standards

All directors, managers and 
employees are expected to act with 
the utmost integrity and objectivity, 
striving at all times to enhance the 
reputation and performance of the 
consolidated entity. Every employee 
has a nominated supervisor to whom 
they may refer any issues arising 
from their employment. 

42

Integrated Research and its controlled entities Annual Report 2016Corporate GovernanceCommunication 
with shareholders

The board provides shareholders with 
information using a comprehensive 
continuous disclosure policy which 
includes identifying matters that 
may have a material effect on the 
price of the company’s securities, 
notifying them to the ASX, posting 
them on the Company’s website 
(www.ir.com), and issuing media 
releases. Disclosures under this 
policy are in addition to the periodic 
and other disclosures required 
under the ASX Listing Rules and 
the Corporations Act. More details 
of the policy are available on the 
Company’s website.

The Chief Executive Officer and 
the Chief Financial Officer are 
responsible for interpreting the 
Company’s policy and where 
necessary informing the board. 
The Company Secretary is 
responsible for all communication 
with the ASX.

The board encourages full 
participation of shareholders at the 
Annual General Meeting to ensure 
a high level of accountability and 
identification with the consolidated 
entity’s strategy and goals. 
Important issues are presented to the 
shareholders as single resolutions. 
The external auditor is requested to 
attend the Annual General Meetings 
to answer any questions concerning 
the audit and the content of the 
auditor’s report.

The shareholders are requested 
to vote on the appointment and 
aggregate remuneration of directors, 
the granting of options and shares to 
directors, the Remuneration Report 
and changes to the Constitution. 
Copies of the Constitution are 
available to any shareholder who 
requests it.

Equal employment 
opportunity

The Company has a policy on 
Equal Employment Opportunity 
with the provision that commits 
to a workplace that is free 
of discrimination of all types. 
It is Company policy to hire, develop 
and promote individuals solely on 
the basis of merit and their ability 
to perform without prejudice to 
race, colour, creed, national origin, 
religion, gender, age, disability, 
sexual orientation, marital status, 
membership or non membership of 
a trade union, status of employment 
(whether full or part‑time) or any 
other factors prohibited by law. 
The board is satisfied that the Equal 
Employment Opportunity policy 
is sufficient without the need to 
further establish a separate policy 
on gender diversity as required by 
the ASX Corporate Governance 
Council recommendation. 

Trading in company securities 
by directors and employees

Directors and employees may acquire 
shares in the company, but are 
prohibited from dealing in company 
shares whilst in possession of price 
sensitive information, and except in 
the periods:

 •

 •

From 24 hours to 42 days after 
the release of the company’s 
half‑yearly results announcement.

From 24 hours to 56 days after 
release of the company’s annual 
results announcement.

Directors must obtain the approval 
of the Chairman of the board and 
notify the Company Secretary 
before they buy or sell shares in the 
company, subject to board veto. 
The company advises the ASX of any 
transactions conducted by directors 
in shares in the company.

Participants in the Company’s 
Performance Rights program are 
specifically prohibited to hedge the 
exposure to the Integrated Research 
share price during the vesting 
period in respect of the unvested 
performance rights.

43

Integrated Research and its controlled entities Annual Report 2016 
4444

Integrated Research and its controlled entities Annual Report 2016

Integrated Research and its controlled entities Annual Report 2016Financials

Contents
46  Consolidated statement of comprehensive income
47  Consolidated statement of financial position
48  Consolidated statement of changes in equity
49  Consolidated statement of cash flows
50  Notes to the financial statements

50  Note 1: Significant accounting policies
57  Note 2: Segment reporting
58  Note 3: Business combinations
59  Note 4: Expenditure
59  Note 5: Other gains and (losses) 
59  Note 6: Finance income
59  Note 7: Auditors’ remuneration
60  Note 8: Income tax expense
61  Note 9: Earnings per share
61  Note 10: Cash and cash equivalents
62  Note 11: Trade and other receivables
63  Note 12: Other current assets
63  Note 13: Other financial assets
63  Note 14: Property, plant and equipment
64  Note 15: Deferred tax assets and liabilities
66  Note 16: Intangible assets
67  Note 17: Goodwill
67  Note 18: Trade and other payables
68  Note 19: Employee benefits
69  Note 20: Deferred consideration for acquisition
69  Note 21: Provisions
70  Note 22: Other liabilities
70  Note 23: Capital and reserves
72  Note 24: Financial instruments
76  Note 25: Operating leases
76  Note 26: Consolidated entities
76  Note 27: Reconciliation of cash flows from operating activities
77  Note 28: Key management personnel disclosures
77  Note 29: Related parties
77  Note 30: Parent entity disclosures
78  Note 31: Subsequent events

79 
 Directors’ declaration
80   Independent auditor’s report
83 

 ASX additional information

Integrated Research and its controlled entities Annual Report 2016

45
45

Integrated Research and its controlled entities Annual Report 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consolidated statement of comprehensive income

For the year ended 30 June 2016

In thousands of AUD

Revenue

Revenue from licence fees

Revenue from maintenance fees

Revenue from testing solution services

Revenue from consulting

Total revenue 

Expenditure

Research and development expenses

Sales, consulting and marketing expenses

General and administration expenses

Total expenditure

Other gains and (losses)

Profit before finance income and tax

Finance income

Profit before tax

Income tax expense

Profit for the year

Other comprehensive income

Items that may be reclassified subsequently to profit

Gain/(loss) on cash flow hedge taken to equity

Foreign exchange translation differences

Other comprehensive income

Consolidated

Notes

2016

2015

45,725

27,153

4,288

7,366

84,532

41,031

23,700

‑

5,548

70,279

(13,582)

(44,983)

(5,962)

(12,431)

(35,161)

(5,220)

(64,527)

(52,812)

1,347

1,502

21,352

34

21,386

(5,357)

16,029

18,969

297

19,266

(5,015)

14,251

247

(46)

201

(317)

915

598

4

5

6

8

Total comprehensive income for the year

16,230

14,849

Profit attributable to: 

Members of Integrated Research

Total comprehensive income attributable to:

Members of Integrated Research

16,029

14,251

16,230

14,849

Earnings per share attributable to members of Integrated Research:  

Basic earnings per share (AUD cents)

Diluted earnings per share (AUD cents)

9

9

9.42

9.34

8.41

8.34

The consolidated statement of comprehensive income is to be read in conjunction with the notes to the financial statements set out on pages 50 to 78.

46

Integrated Research and its controlled entities Annual Report 2016Financial Statements 
Consolidated statement of financial position

As at 30 June 2016

In thousands of AUD

Current assets

Cash and cash equivalents

Trade and other receivables

Current tax assets

Other current assets

Total current assets

Non‑current assets

Trade and other receivables

Other financial assets

Property, plant and equipment

Deferred tax assets

Intangible assets

Total non‑current assets

Total assets

Current liabilities

Trade and other payables

Provisions

Income tax liabilities

Deferred revenue

Other current liabilities

Total current liabilities

Non‑current liabilities

Deferred consideration for acquisition

Deferred tax liabilities

Provisions

Deferred revenue

Other non‑current liabilities

Total non‑current liabilities

Total liabilities

Net assets

Equity

Issued capital

Reserves

Retained earnings

Total equity 

Consolidated

Notes

2016

2015

10

11

12

11

13

14

15

16

18

21

22

20

15

21

22

23

23

8,544

29,017

164

1,781

39,506

15,323

25,012

184

1,344

41,863

23,373

13,260

824

1,793

1,492

21,972

49,454

804

1,969

1,342

17,020

34,395

88,960

76,258

8,513

2,618

3,385

20,363

42

34,921

2,036

3,916

981

5,583

477

12,993

7,241

2,327

1,719

18,698

604

30,589

‑

4,408

899

3,825

405

9,537

47,914

40,126

41,046

36,132

1,667

1,726

37,653

41,046

1,667

935

33,530

36,132

The consolidated statement of financial position is to be read in conjunction with the notes to the financial statements set out on pages 50 to 78.

47

Integrated Research and its controlled entities Annual Report 2016Consolidated statement of changes in equity

For the year ended 30 June 2016

Consolidated

In thousands of AUD

Balance at 1 July 2015

Profit for the year

Other comprehensive income 
for the year (net of tax)

Total comprehensive income 
for the year

Share based payments expense

Dividends to shareholders

Share  
capital

1,667

‑

‑

‑

‑

‑

Balance at 30 June 2016

1,667

Consolidated

In thousands of AUD

Balance at 1 July 2014

Profit for the year

Other comprehensive income 
for the year (net of tax)

Total comprehensive income 
for the year

Share based payments expense

Dividends to shareholders

Share  
capital

1,667

‑

‑

‑

‑

‑

Hedging  
reserve

Translation 
reserve

(197)

‑

247

(439)

‑

(46)

247

(46)

Employee 
benefit 
reserve

1,571

‑

‑

‑

Retained 
earnings

33,530

16,029

‑

Total 

36,132

16,029

201

16,029

16,230

‑

‑

50

‑

‑

590

‑

590

‑

(11,906)

(11,906)

(485)

2,161

37,653

41,046

Hedging  
reserve

Translation 
reserve

Employee 
benefit 
reserve

(1,354)

873

120

‑

(317)

(317)

‑

‑ 

‑

915

915

‑

‑

Retained 
earnings

29,441

14,251

‑

Total 

30,747

14,251

598

14,251

14,849

‑

‑

‑

698

‑

1,571

‑

(10,162)

33,530

698

(10,162)

36,132

Balance at 30 June 2015

1,667

(197)

(439)

The consolidated statement of changes in equity is to be read in conjunction with the notes to the financial statements set out on pages 50 to 78.

48

Integrated Research and its controlled entities Annual Report 2016Financial StatementsConsolidated statement of cash flows

For the year ended 30 June 2016

In thousands of AUD

Cash flows from operating activities

Cash receipts from customers 

Cash paid to suppliers and employees

Cash generated from operations

Income taxes paid

Net cash provided by operating activities

Cash flows from investing activities

Payments for capitalised development

Payments for property, plant and equipment

Payments for purchase of business

Payments for intangible asset

Interest received

Interest paid

Net cash used in investing activities

Cash flows from financing activities

Proceeds from borrowings

Repayment of borrowings

Payment of dividend

Net cash used in financing activities

Net (decrease)/ increase in cash and cash equivalents

Cash and cash equivalents at 1 July

Effects of exchange rate changes on cash

Cash and cash equivalents at 30 June

Consolidated

Notes

2016

2015

27

3

23

74,354

62,012

(54,446)

(38,855)

19,908

(3,690)

16,218

(9,565)

(311)

(1,211)

(152)

154

(120)

23,157

(1,738)

21,419

(9,037)

(1,004)

‑

(126)

297

‑

(11,205)

(9,870)

1,500

(1,500)

(11,906)

(11,906)

(6,893)

15,323

114

‑

‑

(10,162)

(10,162)

1,387

13,300

636

10

8,544

15,323

The consolidated statement of cash flows is to be read in conjunction with the notes to the financial statements set out on pages 50 to 78.

49

Integrated Research and its controlled entities Annual Report 2016 
Notes to the 
Financial 
Statements

For the year ended 
30 June 2016

50

Note 1: Significant accounting policies

Integrated Research Limited 
(the “Company”) is a company 
domiciled in Australia. The financial 
report of the Company for the year 
ended 30 June 2016 comprises 
the Company and its subsidiaries 
(together referred to as the 
“consolidated entity”).

The financial report was authorised 
for issue by the directors on 
22 August 2016.

Integrated Research is a for‑profit 
Company limited by ordinary shares.

a.  Statement of Compliance

The financial report is a general 
purpose financial report which 
has been prepared in accordance 
with Australian Accounting 
Standards and Interpretations 
and the Corporations Act 2001. 
Financial statements of the 
consolidated entity comply with 
International Financial Reporting 
Standards and interpretations 
adopted by the International 
Accounting Standards Board.

b.  Basis of Preparation

The financial statements are 
presented in Australian dollars 
and are prepared on the historical 
cost basis, with the exception 
of derivatives, which are at 
fair value.

The company is of a kind referred 
to in ASIC Legislative Instrument 
2016/191 and in accordance with 
that Class Order, amounts in the 
financial report and Directors’ 
Report have been rounded off 
to the nearest thousand dollars, 
unless otherwise stated.

The preparation of financial 
statements in conformity with 
Australian Accounting Standards 
requires management to make 
judgements, estimates and 
assumptions that affect the 
application of policies and 
reported amounts of assets and 
liabilities, income and expenses. 
The estimates and associated 
assumptions are based on 
historical experience and various 
other factors that are believed 
to be reasonable under the 

circumstances, the results of 
which form the basis of making 
the judgements about carrying 
values of assets and liabilities 
that are not readily apparent 
from other sources. Actual results 
may differ from these estimates. 
These accounting policies have 
been consistently applied by each 
entity in the consolidated entity.

The estimates and underlying 
assumptions are reviewed 
on an ongoing basis. 
Revisions to accounting estimates 
are recognised in the period in 
which the estimate is revised 
if the revision affects only that 
period or in the period of the 
revision and future periods if the 
revision affects both current and 
future periods.

New accounting standards 
and Interpretations 

The Company has applied 
the following standards and 
amendments for the first time 
for the annual reporting period 
commencing 1 July 2015 and 
have not had any material 
effect on its financial position 
or performance:

 • AASB2012‑3 ‘Amendments 
to Australian Accounting 
Standards ‑ Offsetting 
Financial Assets and 
Financial Liabilities’

 • AASB 2013‑3 ‘Amendments 
to Australian Accounting 
Standards ‑ Recoverable 
Amount Disclosures for 
Non‑Financial Assets’

 • AASB 1031 ‘Materiality’

 • AASB2013‑9 ‘Amendments 
to Australian Accounting 
Standards ‑ ‘Conceptual 
Framework, Materiality and 
Financial Instruments’

 • AASB 2014‑1 Part 

A ‘Annual Improvements 
2010‑2012 Cycle’

 • AASB 2014‑1 Part 

A ‘Annual Improvements 
2011‑2013 Cycle’

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 1: Significant accounting policies (cont.)

Standards and Interpretations 
issued not yet effective

At the date of authorisation 
of the financial report, 
a number of standards and 
Interpretations were in issue 
but not yet effective.

Initial application of the 
following Standards is not 
expected to materially affect 
any of the amounts recognised 
in the financial statements, but 
may change the disclosures 
presently made in relation 
to the consolidated entity’s 
financial statements:

Standard/Interpretation

Effective for 
annual reporting 
periods beginning 
on or after

Expected to be 
initially applied 
in the financial 
year ending

AASB 9 ‘Financial Instruments’

1 January 2018

30 June 2018

AASB 2014‑4 ‘Clarification of Acceptable 
Methods of Depreciation and Amortisation 
(Amendments to AASB 116 and AASB 138)’

AASB 2015‑1 ‘Amendments to Australian 
Accounting Standards ‑ Annual 
Improvements 2012‑2014 Cycle’

AASB 2015‑3 ‘Amendments to Australian 
Accounting Standards arising from the 
Withdrawal of AASB1031 Materiality’

1 January 2016

30 June 2016

1 January 2016

30 June 2016

1 July 2015

30 June 2016

Initial application of the 
following Standard is likely to 
impact the amounts recognised 
in the financial statements. 
The Company is still assessing 
the impact of these standards.

Standard/Interpretation

AASB 15 ‘Revenue from Contracts 
with Customers’

Effective for 
annual reporting 
periods beginning 
on or after

Expected to be 
initially applied 
in the financial 
year ending

1 January 2018

30 June 2018

AASB 16 ‘Leases’

1 January 2019

30 June 2019

51

Integrated Research and its controlled entities Annual Report 2016Note 1: Significant 
accounting policies (cont.)

The accounting policies set out 
below have been applied consistently 
to all periods presented in the 
consolidated financial statements.

c.  Basis of consolidation

Subsidiaries are entities 
controlled by the Company. 
Control is achieved when the 
Company is exposed, or has 
rights, to variable returns from 
its involvement with the investee 
and has the ability to affect 
those returns through its power 
over the investee. Specifically, 
the Company controls an investee 
if and only if the Company 
has power over the investee 
(i.e. existing rights that give it 
the current ability to direct the 
relevant activities of the investee). 
Exposure, or rights, to variable 
returns from its involvement with 
the investee, and the ability to 
use its power over the investee to 
affect its returns.

When the Company has less 
than a majority of the voting 
or similar rights of an investee, 
the Company considers all 
relevant facts and circumstances 
in assessing whether it has 
power over an investee including: 
the contractual arrangement 
with the other vote holders of the 
investee; rights arising from other 
contractual arrangements and 
the Company’s voting rights and 
potential voting rights. 

The Company re‑assesses 
whether or not it controls 
an investee if facts and 
circumstances indicate that 
there are changes to one or 
more of the three elements 
of control. Consolidation of a 
subsidiary begins when the 
Company obtains control over 
the subsidiary and ceases when 
the Company loses control of 
the subsidiary. Assets, liabilities, 
income and expenses of a 
subsidiary acquired or disposed 
of during the year are included in 
the statement of comprehensive 
income from the date the 
Company gains control until the 
date the Company ceases to 
control the subsidiary.

Profit or loss and each component 
of other comprehensive 
income (OCI) are attributed to 
the equity holders of the parent 
of the Company and to the 
non‑controlling interests, even if 
this results in the non‑controlling 
interests having a deficit balance. 
When necessary, adjustments are 
made to the financial statements 
of subsidiaries to bring their 
accounting policies into line 
with the Company’s accounting 
policies. All intra‑group assets 
and liabilities, equity, income, 
expenses and cash flows relating 
to transactions between members 
of the Company are eliminated in 
full on consolidation.

A change in the ownership 
interest of a subsidiary, without 
a loss of control, is accounted 
for as an equity transaction. 
If the Company loses control over 
a subsidiary, it: de‑recognises 
the assets (including goodwill) 
and liabilities of the subsidiary; 
de‑recognises the carrying 
amount of any non‑controlling 
interests; de‑recognises the 
cumulative translation differences 
recorded in equity; recognises 
the fair value of the consideration 
received; recognises the fair 
value of any investment retained; 
recognises any surplus or deficit 
in profit or loss; reclassifies the 
parent’s share of components 
previously recognised in OCI to 
profit or loss or retained earnings, 
as appropriate, as would be 
required if the Company had 
directly disposed of the related 
assets or liabilities.

d.  Foreign currency

In preparing the financial 
statements of the individual 
entities transactions in foreign 
currencies are translated at the 
foreign exchange rate ruling 
at the date of the transaction. 
Monetary assets and liabilities 
denominated in foreign 
currencies at the year‑end date 
are translated to Australian 
dollars at the foreign exchange 
rate ruling at that date. Foreign 
exchange differences arising on 
translation are recognised in profit 
or loss. Non‑monetary assets and 
liabilities that are measured in 
terms of historical cost in a foreign 
currency are translated using 

the exchange rate at the date of 
the transaction. Non‑monetary 
assets and liabilities denominated 
in foreign currencies that are 
stated at fair value are translated 
to Australian dollars at foreign 
exchange rates ruling at the dates 
the fair value was determined.

On consolidation, the assets and 
liabilities of foreign operations, 
including goodwill and fair 
value adjustments arising on 
consolidation are translated 
to Australian dollars at foreign 
exchange rates ruling at the 
year end date. The revenues and 
expenses of foreign operations, 
are translated to Australian 
dollars at rates approximating 
the foreign exchange rates ruling 
at the dates of the transactions. 
Foreign exchange differences 
arising on retranslation are 
recognised directly in other 
comprehensive income 
and accumulated in the 
translation reserve.

e.  Fair value measurement

Fair value is the price that would 
be received to sell an asset or 
paid to transfer a liability in an 
orderly transaction between 
market participants at the 
measurement date. The fair value 
measurement is based on the 
presumption that the transaction 
to sell the asset or transfer the 
liability takes place either:

i) 

ii) 

in the principal market for the 
assets or liability; or

in the absence of a 
principal market, in the most 
advantageous market for 
the asset or liability. 

The principal or the most 
advantageous market must be 
accessible by the Company.

The fair value of an asset or 
a liability is measured using 
the assumptions that market 
participants would use when 
pricing the asset or liability, 
assuming that market participants 
act in their economic best interest.

52

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 1: Significant 
accounting policies (cont.)

 f.  Derivative financial 

instruments

A fair value measurement of a 
non‑financial asset takes into 
account a market participant’s 
ability to generate economic 
benefits by using the asset in its 
highest and best use or by selling 
it to another market participant 
that would use the asset in its 
highest and best use.

The Company uses valuation 
techniques that are appropriate 
in the circumstances and 
for which sufficient data are 
available to measure fair value, 
maximising the use of relevant 
observable inputs and minimising 
the use of unobservable inputs.

All assets and liabilities for which 
fair value is measured or disclosed 
in the financial statements are 
categorised within the fair value 
hierarchy, described as follows, 
based on the lowest level input 
that is significant to the fair value 
measurement as whole:

Level 1 ‑ Quoted (unadjusted) 
market prices in active markets 
for identical assets or liabilities

Level 2 ‑ Valuation techniques 
for which the lowest level input 
that is significant to the fair 
value measurement is directly or 
indirectly observable.

Level 3 ‑ Valuation techniques 
for which the lowest level input 
that is significant to the fair value 
measurement is unobservable.

For assets and liabilities that 
are recognised in the financial 
statements at fair value on a 
recurring basis, the Company 
determines whether transfers 
have occurred between levels 
in the hierarchy by re‑assessing 
categorisation (based on 
the lowest level input that is 
significant to the fair value 
measurement as a whole) at the 
end of each reporting period.

The consolidated entity uses 
derivative financial instruments 
to hedge its exposure to 
foreign exchange risks arising 
from operational activities. 
In accordance with its treasury 
policy, the consolidated entity 
does not hold or issue derivative 
financial instruments for 
trading purposes. 

Derivative financial instruments 
are recognised initially at 
fair value. Subsequent to initial 
recognition, derivative financial 
instruments are stated at 
fair value. The gain or loss on 
remeasurement to fair value 
is recognised immediately in 
profit or loss. However, where 
derivatives qualify for hedge 
accounting, recognition of any 
resultant gain or loss depends 
on the nature of the item 
being hedged.

The fair value of forward 
exchange contracts is their 
quoted market price at the year 
end date, being the present value 
of the quoted forward price.

g.  Hedging 

On entering into a hedging 
relationship, the consolidated 
entity normally designates 
and documents the hedge 
relationship and risk 
management objective and 
strategy for undertaking 
the hedge. The documentation 
includes identification of the 
hedging instrument, the hedged 
item or transaction, the nature of 
the risk being hedged and how 
the entity will assess the hedging 
instrument’s effectiveness 
in offsetting the exposure to 
changes in the item’s fair value 
or cash flows attributable to the 
hedged risk. Such hedges are 
expected to be highly effective in 
offsetting changes in fair value 
or cash flows and are assessed 
on an ongoing basis to determine 
that they actually have been 
highly effective throughout the 
financial reporting periods for 
which they are designated. 

For cash flow hedges, the 
associated cumulative gain or 
loss is removed from equity and 

recognised in profit or loss in the 
same period or periods during 
which the hedged forecast 
transaction affects profit or loss. 
The ineffective part of any gain or 
loss is recognised immediately in 
the profit or loss.

h.  Property, plant 
and equipment

Items of property, plant and 
equipment are stated at cost or 
deemed cost less accumulated 
depreciation and impairment 
losses (see accounting policy (l)). 
The cost of acquired assets 
includes (i) the initial estimate 
at the time of installation 
and during the period of use, 
when relevant, of the costs of 
dismantling and removing the 
items and restoring the site on 
which they are located, and 
(ii) changes in the measurement 
of existing liabilities recognised 
for these costs resulting from 
changes in the timing or outflow 
of resources required to settle the 
obligation or from changes in the 
discount rate.

Where parts of an item of 
property, plant and equipment 
have different useful lives, 
they are accounted for as 
separate items of property, 
plant and equipment.

Depreciation is provided on 
property, plant and equipment. 
Depreciation is calculated 
on a straight line basis so as 
to write off the net cost of 
each asset over its expected 
useful life to its estimated 
residual value. Leasehold 
improvements are depreciated 
over the period of the lease or 
estimated useful life, whichever 
is the shorter, using the straight 
line method. The estimated 
useful lives, residual values 
and depreciation method are 
reviewed annually, with the effect 
of any changes recognised on a 
prospective basis.

The following useful lives are used 
in the calculation of depreciation:

 • Leasehold improvements: 

6 to 10 years

 • Plant and equipment: 

4 to 8 years

53

Integrated Research and its controlled entities Annual Report 2016Note 1: Significant 
accounting policies (cont.)

j.   Trade and 

other receivables

Trade and other receivables are 
stated at their amortised cost less 
impairment losses. The carrying 
amount of uncollectible trade 
receivables is reduced by an 
impairment loss through the use 
of an allowance account. 

For the trade receivables with 
extended payment terms beyond 
twelve months, the receivable is 
initially recognised at fair value 
calculated by applying a discount 
to the contracted cash flows. 
The discount rate applied is 
based upon the corporate 
borrowing rate that would apply 
to the type of customer, taking 
into account the customers’ 
credit worthiness based on its size 
and jurisdiction.

In assessing value in use, 
the estimated future cash flows 
are discounted to their present 
value using a pre‑tax discount 
rate that reflects current market 
assessments of the time value of 
money and their risk specific to 
the asset. For an asset that does 
not generate largely independent 
cash inflows, the recoverable 
amount is determined for the 
cash‑generating unit to which 
the asset belongs.

m. Employee benefits

Superannuation

Obligations for contributions to 
defined contribution pension 
plans are recognised as an 
expense in profit or loss as 
incurred. There are no defined 
benefit plans in operation.

k.  Cash and cash equivalents

Long‑term service benefits

Cash and cash equivalents 
comprises cash balances and call 
deposits with an original maturity 
of three months or less. 

l.   Impairment

The carrying amounts of the 
consolidated entity’s assets are 
reviewed at each reporting date 
to determine whether there is any 
indication of impairment. If any 
such indication exists, the asset’s 
recoverable amount is estimated.

For intangible assets that 
are not yet available for use, 
the recoverable amount is 
estimated at each year end date.

An impairment loss is 
recognised whenever the 
carrying amount of an asset 
or its cash generating unit 
exceeds its recoverable amount. 
Impairment losses are recognised 
in profit or loss unless the asset 
has previously been revalued, 
in which case the impairment 
loss is recognised as a reversal 
to the extent of that previous 
revaluation with any excess 
recognised through profit or loss.

The recoverable amount of other 
assets is the greater of their 
fair value less costs to sell and 
value in use.

The consolidated entity’s net 
obligation in respect of long‑term 
service benefits, other than 
pension plans, is the amount of 
future benefit that employees 
have earned in return for their 
service in the current and 
prior periods. The obligation is 
calculated using expected future 
increases in wage and salary 
rates including related on‑costs 
and expected settlement dates, 
and is discounted using the 
rates attached to the Corporate 
bond rate at the year end date 
which have maturity dates 
approximating to the terms of the 
consolidated entity’s obligations.

Share‑based payment transactions

The performance rights 
programmes allow the 
consolidated entity’s employees 
to acquire shares of the Company. 
The fair value of performance 
rights granted are recognised 
as an employee expense with a 
corresponding increase in equity. 
The fair value is measured at grant 
date and spread over the period 
during which the employees 
become unconditionally entitled 
to the performance rights. The fair 
value of the instrument granted is 
measured using a binomial option 
pricing model, taking into account 
the terms and conditions upon 
which the options were granted. 

i.   Intangible Assets

Research and development

Expenditure on research 
activities, undertaken with the 
prospect of gaining new scientific 
or technical knowledge and 
understanding, is recognised in 
profit or loss as incurred.

Expenditure on development 
activities, whereby research 
findings are applied to a plan or 
design for the production of new 
or substantially improved products 
and processes, is capitalised 
if the product or process is 
technically and commercially 
feasible and the consolidated 
entity has sufficient resources to 
complete development.

The useful lives of the capitalised 
assets are assessed as finite.

The expenditure capitalised 
includes the cost of materials, 
direct labour and an appropriate 
proportion of overheads. Other 
development expenditure is 
recognised in profit or loss as an 
expense as incurred. Capitalised 
development expenditure is 
stated at cost less accumulated 
amortisation and impairment 
losses (see accounting policy (l)).

Amortisation is charged to profit 
or loss on a straight‑line basis over 
the estimated useful life, but no 
more than three years.

Intellectual property

Intellectual property acquired 
from third parties is amortised 
over its estimated useful life, 
but no more than three years.

Computer software

Computer software is stated 
at cost and depreciated on a 
straight‑line basis over a 2½ to 
3 year period. 

Customer relationships

Customer relationships are initially 
measured at fair value and 
amortised over the estimated useful 
life, but no more than five years.

54

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 1: Significant 
accounting policies (cont.)

The amount recognised as an 
expense is adjusted to reflect the 
actual number of share options 
or performance rights that are 
expected to vest.

Wages, salaries, annual leave, 
and non‑monetary benefits

Liabilities for employee benefits 
for wages, salaries and annual 
leave represent present 
obligations resulting from 
employees’ services provided to 
the year end date, calculated at 
undiscounted amounts based on 
remuneration wage and salary 
rates that the consolidated entity 
expects to pay as at the year 
end date.

n.  Provisions

A provision is recognised in the 
statement of financial position 
when the consolidated entity has 
a present legal or constructive 
obligation as a result of a 
past event, and it is probable 
that an outflow of economic 
benefits will be required to settle 
the obligation. Provisions are 
determined by discounting the 
expected future cash flows at a 
pre‑tax rate that reflects current 
market assessments of the time 
value of money and, where 
appropriate, the risks specific to 
the liability.

Employee benefits 

Provisions for employee benefits 
include liabilities for annual 
leave and long service leave and 
are measured at the amounts 
expected to be paid when the 
liabilities are settled. 

Make good

The make good provision 
is for leases undertaken by 
the Company. For each provision 
raised a corresponding asset has 
been recognised and is amortised 
over the shorter of the term of 
the lease or the useful life of 
the asset.

o.  Trade and other payables

q.  Expenses

Trade and other payables are 
stated at their amortised cost.

p.  Revenue

The consolidated entity allocates 
revenue to each element in 
software arrangements involving 
multiple elements based on the 
relative fair value of each element. 
The typical elements in the 
multiple element arrangement are 
licence and maintenance fees. 
The company’s determination of 
fair value is generally based on 
the price charged when the same 
element is sold separately.

Revenue from the sale of licences, 
where the consolidated entity has 
no post delivery obligations to 
perform is recognised in profit or 
loss at the date of delivery of the 
licence key.

Revenue from maintenance 
contracts is recognised rateably 
over the term of the service 
agreement, which is typically 
one year. Maintenance contracts 
are typically priced based on a 
percentage of licence fees and 
have a one year term. Services 
provided to customers under 
maintenance contracts include 
technical support and supply of 
software updates.

The Company introduced a new 
line of revenue (testing solutions 
services) following the acquisition 
of the IQ Services business. 
Revenue from testing solutions 
services is recognised over the 
period the services are provided.

Revenue from multiple element 
software arrangements, where 
the fair value of an undelivered 
element cannot be reliably 
measured are recognised over 
the period the undelivered 
services are provided.

Revenue from consulting services 
is recognised over the period the 
services are provided. 

No revenue is recognised if there 
are significant uncertainties 
regarding the recovery of the 
consideration due, the costs 
incurred or to be incurred cannot 
be measured reliably, there is a 
risk of return of goods or there 
is continuing management 
involvement with the goods.

Operating lease payments

Payments made under operating 
leases are recognised in profit 
or loss on a straight‑line basis 
over the term of the lease. 
Lease incentives received are 
recognised in profit or loss as an 
integral part of the total lease 
expense and spread over the 
lease term.

Financing income

Financing income comprises 
interest receivable on 
funds invested.

r.   Income tax

Income tax on the profit or 
loss for the periods presented 
comprises current and deferred 
tax. Income tax is recognised in 
profit or loss except to the extent 
that it relates to items recognised 
directly in equity, in which case it 
is recognised in equity.

Current tax is the expected tax 
payable on the taxable income 
for the year, using tax rates 
enacted or substantively enacted 
at the year end date, and any 
adjustment to tax payable in 
respect of previous years.

Deferred tax is recognised 
on temporary differences 
between the carrying amounts 
of assets and liabilities for 
financial reporting purposes 
and the amounts used for 
taxation purposes. The amount 
of deferred tax provided is based 
on the expected manner of 
realisation or settlement of the 
carrying amount of assets and 
liabilities, using tax rates enacted 
or substantively enacted at the 
year end date.

A deferred tax asset is recognised 
only to the extent that it is 
probable that future taxable 
profits will be available against 
which the asset can be utilised. 
Deferred tax assets are reduced 
to the extent that it is no longer 
probable that the related tax 
benefit will be realised.

Additional dividend franking deficit 
tax that arises from the distribution 
of dividends are recognised at the 
same time as the liability to pay the 
related dividend.

55

Integrated Research and its controlled entities Annual Report 2016Receivables

The consolidated entity assesses 
impairment of receivables 
based on objective evidence 
for significant receivables and 
by placing non‑significant 
receivables in portfolios of 
similar risk profiles, based 
on objective evidence 
from historical experience 
adjusted for any effects of 
conditions existing at each 
reporting date. This assessment 
includes judgements and 
estimates of future outcomes 
the actual results of which may 
differ from the estimates at the 
reporting date.

u.  Business Combination 

and Goodwill

Business combinations are 
accounted for using the 
acquisition method. The cost of 
an acquisition is measured as the 
aggregate of the consideration 
transferred at acquisition 
date measured at fair value. 
Any contingent consideration to 
be transferred by the acquirer 
will be recognised at fair 
value at the acquisition date. 
Changes in the fair value of the 
contingent consideration are 
recognised in the Statement of 
Comprehensive Income.

Goodwill is initially measured 
at cost, being the excess of the 
aggregate of the consideration 
transferred over the net 
identifiable assets acquired 
and liabilities assumed. 
Goodwill is tested annually for 
impairment. Acquisition‑related 
costs are expensed as 
incurred and included in 
administrative expenses.

Note 1: Significant 
accounting policies (cont.)

s. Goods and Services Tax

Revenue, expenses and assets 
are recognised net of the amount 
of goods and services tax (GST), 
or similar taxes, except where the 
amount of GST incurred is not 
recoverable from the taxation 
authority. In these circumstances, 
the GST is recognised as part 
of the cost of acquisition of the 
asset or as part of the expense.

Receivables and payables are 
stated with the amount of 
GST included. The net amount 
of GST recoverable or payable 
is included as a current asset 
or liability in the statement of 
financial position.

Cash flows are included in the 
statement of cash flows on a 
gross basis. The GST components 
of cash flows arising from 
investing and financing activities, 
which are recoverable or payable 
are classified as operating 
cash flows.

t.   Significant accounting 
judgements, estimates 
and assumptions

The carrying amounts of 
certain assets and liabilities 
are often determined based on 
estimates and assumptions of 
future events. The key estimates 
and assumptions that have 
a significant risk of causing 
a material adjustment to the 
carrying amounts of certain 
assets and liabilities within the 
next annual reporting period are:

Intangible assets ‑ Development

An intangible asset arising from 
development expenditure on an 
internal project is recognised 
only when the consolidated 
entity can demonstrate the 
technical feasibility of completing 
the intangible asset so that it 
will be available for use or sale, 
its intention to complete and its 

ability to use or sell the asset, 
how the asset will generate 
future economic benefits, the 
availability of resources to 
complete the development and 
the ability to measure reliably 
the expenditure attributable to 
the intangible asset during its 
development. Following the initial 
recognition of the development 
expenditure, the cost model 
is applied requiring the asset 
to be carried at cost less any 
accumulated amortisation and 
accumulated impairment losses. 
Any expenditure so capitalised 
is amortised over the period 
of expected benefits from the 
related project commencing 
from the commercial release of 
the project. The carrying value 
of an intangible asset arising 
from development expenditure 
is tested for impairment 
annually when the asset is not 
yet available for use or more 
frequently when an indication 
of impairment arises during the 
reporting period.

Intangible assets ‑ Goodwill

Goodwill acquired from business 
acquisitions is initially measured 
at cost. Good is tested annually 
for impairment or earlier if 
changes in circumstances 
indicate a potential impairment, 
the impairment policy is explained 
in note 1(l). The impairment 
testing requires judgements 
over future cashflow streams 
and assumptions used in 
the calculations.

Share based 
payment transactions

The consolidated entity measures 
the cost of equity‑settled 
transactions with employees by 
reference to the fair value of the 
equity instruments at the date at 
which they are granted. The fair 
value is determined by using a 
binomial option pricing model 
and applying management 
determined probability 
factors relating to non‑market 
vesting conditions.

56

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 2: Segment reporting

The information reported to the CODM (being the Chief Executive Officer) for the purposes of resource allocation 
and assessment of performance is focused on geographical performance. The principal geographical regions are 
The Americas ‑ Operating from the United States with responsibility for the countries in North, Central and South America, 
Europe ‑ operating from the United Kingdom with responsibility for the countries in Europe, Asia Pacific ‑ operating from 
Australia and Singapore with responsibility for the countries in the rest of the world and Corporate Australia ‑ includes 
revenue and expenses for research and development and corporate head office functions of the company.

Inter‑segment pricing is determined on an arm’s length basis.

Segment profit represents the profit earned by each segment without allocation of investment revenue and income tax 
expense. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and 
assessment of segment performance.

Information regarding these segments is presented below. The accounting policies of the reportable segments are the 
same as the Group’s accounting policies.

Americas

Europe

Asia Pacific

Corporate 
Australia1

Eliminations

Consolidated

2016

2015

2016

2015

2016

2015

2016

2015

2016

2015

2016

2015

57,956 52,688 17,208 10,182 10,271 8,866

(903)

(1,457)

‑

‑ 84,532 70,279

‑

‑

‑

‑

‑

‑ 41,006 38,109 (41,006) (38,109)

‑

‑

57,956 52,688 17,208 10,182 10,271 8,866 40,103 36,652 (41,006) (38,109) 84,532 70,279

In thousands of 
AUD

Sales to customers 
outside the 
consolidated entity

Inter‑segment 
revenue

Total segment 
revenue

Total revenue

84,532 70,279

‑

21,352 18,969

21,352 18,969

34

297

(5,357)

(5,015)

16,029 14,251

2,535

1,130

10,636

9,114

‑

‑

‑

‑

‑

Segment results

3,160

1,598

426

248

359

222

17,407 16,901

Results from 
operating activities

Financing income

Income tax 
expense

Profit for the year

Capital additions2

1,354

704

49

112

Depreciation 
and amortisation 
expenditure

555

156

86

71

8

7

17

1,124

297

4

9,988 8,883

Americas 
(USD)

Europe 
(GBP)

In local currency3

2016

2015

2016

2015

Sales to customers 
outside the 
consolidated entity

Inter‑segment 
sales

Total segment 
revenue

41,997 43,621

8,438 5,338

‑

‑

‑

‑

41,997 43,621

8,438 5,338

Segment results

2,276

1,311

209

133

1   Corporate Australia includes both the research and development, hedging and corporate head office functions of Integrated Research Limited. 

2   Excludes internal development costs capitalised but includes third party assets acquired. Additions also include assets acquired through the purchase 

of businesses.

3   Segment results represented in local currencies as reviewed by the Chief Operating Decision Maker.

57

Integrated Research and its controlled entities Annual Report 2016Note 3: Business combinations

On 1st July 2015, the Company acquired the operational assets of the US based IQ Services business. The acquisition 
provides the Company with a number of strategically significant growth opportunities in its existing markets and into new 
allied markets. The business combination is anticipated to provide the world’s most complete view of cloud, hybrid and 
traditional on premises operations for unified communications and contact centre solutions.

The acquisition has been accounted for using the acquisition method. The interim consolidated financial statements 
include the results of the acquired business for the six month period from the acquisition date.

The fair values of the identifiable assets and liabilities of the acquired business on 1 July 2015 were as follows:

In thousands of AUD

Assets:
Prepayments
Property, plant and equipment
Capitalised Development
Customer relationships
Third party software
Total Assets

Liabilities:
Provisions
Deferred revenue
Total Liabilities
Total identifiable net assets at fair value 
Goodwill arising on acquisition
Total Net Assets Acquired

Represented by:
Payment due on acquisition date
Deferred consideration within one year
Deferred consideration beyond one year 
Purchase consideration

Notes

Fair value 
recognised on 
acquisition

16
16
16

16

52
335
844
779
94
2,104

159
752
911
1,193
3,204
4,397

325
845
3,227
4,397

The goodwill recognised at acquisition is primarily attributed to the expected synergies and other benefits from 
combining the assets and activities of IQ Services with those of the Company. The goodwill has been tested for 
impairment at 30 June 2016 (refer note 17). 

The deferred consideration recognised at acquisition date represents Company’s estimate of the fair value of future 
payments for the acquisition after taking into account the following inputs:

 • an implicit finance charge to discount the obligations to net present value;

 •

 •

the currency exchange rate since the obligations are due in United States dollars; and

the probability of the vendor achieving certain earn‑out targets. 

At 30 June 2016, the Company revised its fair value of the deferred consideration liability to $2,036,000, resulting in a 
credit to profit of $1,413,000. The write‑back reflects the fair value of the deferred consideration based on the current 
year actual results and revised forecast EBITDA for FY17 and FY18. The contingent consideration is based upon IQ 
Services achieving EBITDA milestones over the three years between 1 July 2015 and 30 June 2018. There are catch‑up 
mechanisms over the three year period with the potential final payment ranging between $nil and $3.5 million.

The table below provides the movement of the deferred consideration during the year:

In thousands of AUD

Payment at acquisition
Deferred consideration 

Purchase 
consideration 
at acquisition

Cash paid 
during the 
period

Currency 
revaluation

Finance 
charges

Writeback of 
liability

Deferred 
consideration 
at end of year

325
4,072
4,397

(325)
(886)
(1,211)

‑
182
182

‑
81
81

‑
(1,413)
(1,413)

‑
2,036
2,036

58

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 4:  
Expenditure

In thousands of AUD

Total expenditure includes:

Employee benefits expense:

Defined contribution plans

Equity settled share‑based payments

Other employee benefits

Depreciation and amortisation

Bad and doubtful debt expense

Operating lease rental expenses

Note 5:  
Other gains and (losses)

In thousands of AUD

Writeback of deferred consideration 
for acquisition

Currency exchange gains/(losses)

Note

3

Note 6:  
Finance income

In thousands of AUD

Interest income

Finance charges on earn out liability

Interest on borrowings

Note 7: 
Auditors’ remuneration

2016 and 2015 Ernst and Young. 

In AUD

Remuneration for audit and review of 
the financial reports of the Company or 
any entity in the consolidated entity:

Audit and review of financial reports:

Auditors of the Company 

Remuneration for other services by the 
auditors of the Company or any entity in 
the consolidated entity:

Taxation services:

Auditors of the Company 

Consolidated

2016

2015

2,218

655

43,562

46,435

10,636

1,463

1,912

1,872

728

36,504

39,104

9,114

1,004

1,600

Consolidated

2016

1,413

(66)

1,347

Consolidated

2016

154

(81)

(39)

34

2015

‑

1,502

1,502

2015

297

‑

‑

297

Consolidated

2016

2015

200,850

142,509

12,448

86,251

216,800

157,460

59

Integrated Research and its controlled entities Annual Report 2016Note 8: 
Income tax expense 

Recognised in profit for the year

In thousands of AUD

Current tax expense:

Current year

Prior year adjustments

Deferred tax expense:

Origination and reversal of 
temporary differences

Total income tax expense in 
profit and loss

Consolidated

Note

2016

2015

4,589

126

4,715

5,978

(98)

5,880

15

642

(865)

5,357

5,015

Numerical reconciliation between 
income tax expense and profit 
before tax

In thousands of AUD

Profit before tax

Income tax using the domestic corporate tax rate of 30%

Increase in income tax expense due to:

Non‑deductible expenses

Effect of tax rates in foreign jurisdictions

Other

Prior year adjustments

Decrease in income tax expense due to:

R&D tax incentive 

Write‑back of deferred consideration for acquisition

Income tax expense

Consolidated

2016

21,386

6,416

257

192

158

126

2015

19,266

5,780

303

121

244

(98)

(1,273)

(1,335)

(519)

5,357

‑

5,015

60

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 9: Earnings per share

The calculation of basic and diluted earnings per share at 30 June 2016 was based on the profit attributable to 
ordinary shareholders of $16,029,000 (2015: $14,251,000); a weighted number of ordinary shares outstanding during 
the year ended 30 June 2016 of 170,239,391 (2015: 169,409,027); and a weighted number of ordinary shares (diluted) 
outstanding during the year ended 30 June 2016 of 171,653,017 (2015: 170,918,803), calculated as follows:

In thousands of AUD

Profit for the year

Weighted average number of shares used as the denominator

(Number)

Number for basic earnings per share:

Ordinary shares

Effect of employee share plans on issue

Number for diluted earnings per share

Basic earnings per share (AUD cents)

Diluted earnings per share (AUD cents)

Note 10: Cash and cash equivalents

In thousands of AUD

Cash at bank and on hand

Consolidated

2016

16,029

2015

14,251

Consolidated

2016

2015

170,239,391

169,409,027

1,413,626

1,509,776

171,653,017

170,918,803

9.42

9.34

8.41

8.34

Consolidated

2016

8,544

2015

15,323

61

Integrated Research and its controlled entities Annual Report 2016Note 11: 
Trade and other receivables

Current

In thousands of AUD

Trade debtors

Less: Allowance for doubtful debts

GST receivable

Non‑current

In thousands of AUD

Trade debtors

Consolidated

2016

2015

30,763 

25,768 

(1,860)

28,903

114

(852)

24,916

96

29,017

25,012

Consolidated

2016

23,373

2015

13,260

The credit period on sales ranges from 30 to 90 days. Customers of good credit 
worthiness can request for extended payment plans over the committed term of 
the licence contract which typically is up to three years. 

Ageing of past due but not impaired:

Consolidated

In thousands of AUD

Past due 30 days

Past due 60 days

Past due 90 days

Total

The movement in the allowance for doubtful debts in 
respect of trade receivables is detailed below:

In thousands of AUD

Balance at beginning of year

Amounts written off during the year

Increase in provision

Balance end of year

2016

832

1,200

374

2,406

Consolidated

2016

852

(455)

1,463

1,860

2015

873

1,697

654

3,224

2015

858

(1,010)

1,004

852

The consolidated entity has used the following criteria to assess the allowance loss 
for trade receivables and as a result is unable to specifically allocate the allowance 
to the ageing categories shown above:

 • historical bad debt experience;

 •

the general economic conditions;

 • an individual account by account specific risk assessment based on past 

credit history; and

 • any prior knowledge of debtor insolvency or other credit risk.

Included in the consolidated entity’s trade receivable balance are debtors which 
are 90 days past due at the reporting date which the consolidated entity has not 
provided for as there has been no significant change in credit quality and the 
consolidated entity believes that the amounts are still considered recoverable. 
The consolidated entity does not hold any collateral over these balances.

62

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 12: 
Other current assets

In thousands of AUD

Other prepayments

Fair value of hedge asset ‑ forward foreign 
exchange contracts

Note 13: 
Other financial assets

In thousands of AUD

Deposits

Consolidated

2016

1,607

174

1,781

2015

1,325

19

1,344

Consolidated

2016

824

2015

804

The carrying amount of other financial assets is a reasonable approximation of 
their fair value.

Note 14: 
Property, plant 
and equipment

Plant and Equipment

In thousands of AUD

At cost

Accumulated depreciation

Leasehold Improvements

In thousands of AUD

At cost

Accumulated depreciation

Total property, plant and equipment

In thousands of AUD

At cost

Accumulated depreciation

Total written down amount

Consolidated

2016

3,887

2015

3,389

(2,579)

(2,073)

1,308

1,316

Consolidated

2016

2,368

2015

2,279

(1,883)

(1,626)

485

653

Consolidated

2016

6,255

2015

5,668

(4,462)

(3,699)

1,793

1,969

63

Integrated Research and its controlled entities Annual Report 2016Note 14: 
Property, plant and 
equipment (cont.)

Plant and Equipment

In thousands of AUD

Carrying amount at start of year

Additions

Acquired through business acquisition

Disposals

Effects of foreign currency exchange

Depreciation expense

Carrying amount at end of year

Leasehold Improvements

In thousands of AUD

Carrying amount at start of year

Additions

Acquired through business acquisition

Disposals

Effects of foreign currency exchange

Depreciation expense 

Carrying amount at end of year

Consolidated

2016

1,316

308  

231

(6)

28

(569)

1,308

Consolidated

2016

653

3

104

‑

(11)

(264)

485

2015

933

831

‑

(10)

43

(481)

1,316

2015

747

173

‑

(67)

31

(231)

653

Note 15: Deferred tax assets and liabilities 

Deferred tax assets and liabilities are attributable to the following:

Consolidated

In thousands of AUD

Intangible assets

Trade and other payables

Employee benefits

Provisions

Other current liabilities

Unrealised foreign exchange gain

Unrealised foreign exchange loss

Deferred tax assets/(liabilities)

Set off of deferred tax asset 

Net deferred tax assets/(liabilities)

Assets

Liabilities

Net

2016

‑

355

1,051

774

437

‑

142

2,759

(1,267)

1,492

2015

‑

273

1,117

428

670

‑

‑

2,488

(1,146)

1,342

2016

5,183

2015

5,067

2016

2015

(5,183)

(5,067)

‑

‑

‑

‑

‑

‑

5,183

(1,267)

3,916

‑

‑

‑

‑

487

‑

5,554

(1,146)

4,408

355

1,051

774

437

‑

142

273

1,117

428

670

(487)

‑

(2,424)

(3,066)

‑

‑

(2,424)

(3,066)

64

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 15: Deferred tax assets and liabilities (cont.)

Movement in temporary differences during the year:

For year ended 30 June 2016

Consolidated

In thousands of AUD

Intangible assets

Trade and other payables

Employee benefits

Provisions

Other current liabilities

Unrealised foreign exchange gain

Unrealised foreign exchange loss

Balance 
1 July 15

Recognised  
in income

Recognised  
in equity

Balance  
30 June 16

(5,067)

273

1,117

428

670

(487)

‑

(3,066)

(116)

82

(66)

346

(233)

487

142

642

‑

‑

‑

‑

‑

‑

‑

‑

(5,183)

355

1,051

774

437

‑

142

(2,424)

For year ended 30 June 2015

Consolidated

In thousands of AUD

Intangible assets

Trade and other payables

Employee benefits

Provisions

Other current liabilities

Unrealised foreign exchange gain

Unrealised foreign exchange loss

Balance 
1 July 14

Recognised  
in income

Recognised  
in equity

Balance  
30 June 15

(4,842)

(225)

252

965

416

893

‑

115

(2,201)

21

152

12

(223)

(487)

(115)

(865)

‑

‑

‑

‑

‑

‑

‑

‑

(5,067)

273

1,117

428

670

(487)

‑

(3,066)

65

Integrated Research and its controlled entities Annual Report 2016Consolidated

Software 
development

Third party 
software

Goodwill

Customer 
Relationship

Note 16: Intangible assets

The balance of capitalised intangible assets comprises:

Cost

In thousands of AUD

Balance at 1 July 2014

Fully amortised & offset

Internally developed

Purchased

Effects of foreign currency exchange

26,899

(5,672)

9,037

‑

‑

1,167

(250)

‑

126

14

Balance at 30 June 2015

30,264

1,057

Balance at 1 July 2015

Fully amortised & offset

Acquired through business acquisition

Internally developed

Purchased

Effects of foreign currency exchange

30,264

(8,127)

844

9,565

‑

‑

1,057

‑

94

‑

152

‑

Amortisation

In thousands of AUD

Balance at 1 July 2014

Fully amortised & offset

Amortisation for year

Effects of foreign currency exchange

Balance at 30 June 2015

Balance at 1 July 2015

Fully amortised & offset

Amortisation for year

Effects of foreign currency exchange

10,855

(5,672)

8,253

‑

13,436

13,436

(8,127)

9,421

‑

954

(250)

150

11

865

865

‑

216

(5)

Balance at 30 June 2016

32,546

1,303

3,289

Consolidated

Software 
development

Third party 
software

Goodwill

Customer 
Relationship

‑

‑

‑

‑

‑

‑

‑

‑

3,204

‑

‑

85

‑

‑

‑

‑

‑

‑

‑

‑

779

‑

‑

21

800

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

‑

165

(5)

160

Total

28,066

(5,922)

9,037

126

14

31,321

31,321

(8,127)

4,921

9,565

152

106

37,938

Total

11,809

(5,922)

8,403

11

14,301

14,301

(8,127)

9,802

(10)

15,966

Total

17,020

21,972

Balance at 30 June 2016

14,730

1,076

Carrying amounts

Consolidated

In thousands of AUD

Balance at 30 June 2015

Balance at 30 June 2016

Software 
development

Third party 
software

16,828

17,816

192

227

Goodwill

‑

3,289

Customer 
Relationship

‑

640

66

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 17: Goodwill 

Goodwill through business combination has been allocated to the applicable cash generating unit for impairment testing. 
Management has identified the Group as the cash generating unit (the Prognosis CGU) to which the carrying value 
of goodwill is allocated for impairment testing. Management performs its annual impairment testing at least annually. 
The carrying value of goodwill at 30 June 2016 is $3,289,000. The goodwill resides in the Company’s American 
subsidiary, Integrated Research Inc. and is therefore subject to movements in foreign exchange rates. A reconciliation of 
the movement in goodwill is included in note 16. 

The recoverable amount of the Prognosis CGU has been determined using a value in use approach. The value in use of 
the Prognosis CGU has been based on the detailed financial projections approved by the Board of Directors covering a 
five year period and the terminal value.

The following key assumptions were used for value in use calculation:

1. Cash flow forecasts 

The cash flow forecasts are based upon a Board approved 2017 budget and projections for the subsequent four years of 
the Prognosis CGU.

2. Discount rate 

Discount rate of 11% applied for value in use calculation is based on the post‑tax weighted average of capital cost 
applicable to the Prognosis CGU.

3. Terminal value 

The terminal growth rate after the five year projection period has been calculated using a growth rate of 3% which is 
determined by Management based on their assessment of expected long term annual growth for the software industry.

The impairment testing indicates existence of sufficient headroom in the current year therefore no impairment is 
recognised in the Prognosis CGU at 30 June 2016. 

With regard to the assessment of the value in use of the Prognosis CGU, management believe that a reasonable change 
in any of the above key assumptions would not cause the carrying values to materially exceed their recoverable amounts.

Note 18: 
Trade and other payables

In thousands of AUD

Trade and other creditors

Consolidated

2016

8,513

8,513

2015

7,241

7,241

The average credit period on trade and other payables is 30 days.

67

Integrated Research and its controlled entities Annual Report 2016Note 19: 
Employee benefits

In thousands of AUD

Consolidated

Current

Liability for annual leave

Liability for long service leave

2016

1,889

729

2,618

2015

1,684

643

2,327

Non‑current

Liability for long service leave

408

399

Pension plans

Employees of the consolidated entity accumulate pension benefits through 
statutory contributions by the entities in the consolidated entity as required 
by the laws of the jurisdictions in which they operate, supplemented by 
individual contributions. 

Share based payments

Performance Rights

On 21 November 2011, the consolidated entity established the Integrated 
Research Performance Rights and Options Plan (IRPROP). The plan enables the 
Company to offer performance rights to eligible employees to obtain shares in 
Integrated Research at no cost contingent upon performance conditions being 
met. The performance conditions include either a service period with performance 
components or a service period with a net after tax profit hurdle. The performance 
rights are automatically exercised into shares upon the performance conditions 
being met. The following performance rights were granted during the period:

Grant Date

Oct‑14*

Aug‑15

Dec‑15

Number of 
Rights

Earliest 
Vesting 
Date

Expiry date

250,000

Oct 2016

Oct 2016

94,900

 Aug 2018

Sep 2018

195,000

 Feb 2019

Mar 2019

* This is the third tranche of the original plan granted on 14 November 2013 of 850,000 rights

The fair value of the performance 
rights including assumptions used 
are as follows:

Grant date

Fair value at measurement date

Share price

Exercise price

Expected volatility

Contractual life (expressed in days)

Expected dividends

Risk‑free interest rate  
(based on 3 year treasury bonds)

Aug 2015

Dec 2015

$2.0075

$2.210

$1.8459

$2.090

nil

50%

1,096

3.20%

2.00%

nil

50%

1,193

3.80%

 2.00%

The fair values of services received in return for performance rights granted to 
employees is measured by reference to the fair value of share options granted. 
The estimate of the fair value of the services received is measured based on a 
Binomial option‑pricing model. 

68

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 19 
Employee benefits (cont.)

During the year ended 30 June 2016, the consolidated entity recognised an 
expense through profit of $655,000 related to the fair value of performance rights 
(2015: $728,000).

The following table provides the movement in performance rights during the year:

In thousands of performance rights

Outstanding at the beginning of the year

Forfeited during the year

Exercised during the year

Granted during the year

Outstanding at the end of the year

Exercisable at the end of the year (vested)

Note 20: 
Deferred consideration 
for acquisition

Current

In thousands of AUD

Deferred consideration for acquisition

Note 21: 
Provisions

In thousands of AUD

Current

Employee benefits

Non‑current

Employee benefits

Lease make good

2016

2,405

(186)

(760)

540

1,999

‑

2015

1,937

(465)

(712)

1,645

2,405

‑

Consolidated

2016

2,036

2,036

2015

‑

‑

Consolidated

2016

2,618

2,618

408

573

981

2015

2,327

2,327

399

500

899

Note

3

Note

19

19

69

Integrated Research and its controlled entities Annual Report 2016Note 22: 
Other liabilities

In thousands of AUD

Current

Fair value of hedge liabilities ‑ forward 
foreign exchange contracts

Non‑current

Other creditors

Consolidated

2016

2015

42

604

477

405

Note 23: 
Capital and reserves

Share capital

In thousands of shares

On issue 1 July

Ordinary shares

2016

2015

169,671

168,959

Issued against employee performance right exercised

760

712

On issue 30 June

170,431

169,671

Effective 1 July 1998, the Company Law Reform Act abolished the concept of par 
value shares and the concept of authorised capital. Accordingly, the company 
does not have authorised capital or par value in respect of its issued shares.

The holders of ordinary shares are entitled to receive dividends as declared from 
time to time and are entitled to one vote per share at meetings of the Company. 
All shares rank equally with regard to the Company’s residual assets.

Hedging reserve

The hedging reserve comprises the effective portion of the cumulative net change 
in the fair value of cash flow hedging instruments related to hedged transactions 
that have not yet occurred.

Translation reserve

The translation reserve comprises all foreign exchange differences arising from the 
translation of the financial statements of foreign operations where their functional 
currency is different to the presentation currency of the consolidated entity, as 
well as from the translation of liabilities that hedge the consolidated entity’s net 
investment in a foreign subsidiary.

Employee benefit reserve

The employee benefit reserve arises on the grant of either share options or 
performance rights to employees under the Integrated Research Performance 
Rights and Option Plan (established November 2011) or the Employee Share 
Option Plan (established October 2000). Refer to note 19 for further details.

70

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 23: 
Capital and reserves (cont.)

Dividends

Dividends recognised in the current year by the company are:

In thousands of AUD

per share Total amount

Cents 

Franked/ 
unfranked

Date of 
payment

2016

Final 2015

Interim 2016

Total amount

2015

Final 2014

Interim 2015

Total amount

4.0

3.0

2.5

3.5

6,793 35% franked

22 Sep 2015

5,113 55% franked

20 Apr 2016

11,906

4,224 35% franked

12 Sep 2014

5,938 35% franked 20 Mar 2015

10,162

After the end of the financial year, the following dividend was proposed by 
the directors. The financial effect of this dividend has not been brought to 
account in the financial statements for the year ended 30 June 2016 and will be 
recognised in subsequent financial statements:

In thousands of AUD

Cents 
per share

Total amount

Franked/ 
unfranked

Date of 
payment

Final 2016

3.5

5,970 60% franked

13 Oct 16

The final dividend declared of 3.5 cents together with the interim dividend paid 
in March 2016 of 3.0 cents takes total dividends for the 2016 financial year to 
6.5 cents.

Franking account disclosure:

In thousands of AUD

Adjusted franking account balance

Impact on franking account balance of 
dividends not recognised

Company

2016

1,613

2015

1,020

(1,535)

(1,019)

71

Integrated Research and its controlled entities Annual Report 2016Capital risk management

The consolidated entity manages 
its capital to ensure that controlled 
entities will be able to continue as 
a going concern while maximising 
the return to stakeholders 
through the optimisation of 
treasury management.

The capital structure of the 
consolidated entity consists of cash 
and cash equivalents and equity 
attributable to equity holders of 
the company, comprising issued 
capital, reserves, and retained 
earnings as disclosed in Notes 10 
and 23 respectively.

Borrowing facility 

On 21 December 2015, the 
Company established an AUD 10 
million multicurrency revolving cash 
advance facility. The purpose of the 
facility is to fund working capital 
requirements and the deferred 
consideration for the IQ Services 
business acquisition. The facility was 
drawn down by $1.5 million during the 
year and was repaid before year end.

The facility is secured by a General 
Security Agreement with a deed 
of cross guarantee including the 
parent entity, Integrated Research 
UK Limited, and Integrated Research 
Inc. The facility is also subject to 
certain debt covenants including 
a leverage ratio, interest cover 
ratio and capitalisation ratio. 
The Company met all the covenant 
requirements during the year.

Significant 
accounting policies

Details of the significant accounting 
policies and methods adopted, 
including the criteria for recognition, 
the basis of measurement and the 
basis on which income and expenses 
are recognised, in respect of each 
class of financial asset, financial 
liability and equity instrument 
are disclosed in Note 1 to the 
financial statements.

Financial risk 
management objectives

The Board of Directors has overall 
responsibility for the establishment 
and oversight of the consolidated 
entity’s financial management 
framework. The Board has an 
established Audit and Risk 
Committee, which is responsible 
for developing and monitoring 
the consolidated entity’s 
financial management policies. 
The Committee provides regular 
reports to the Board of Directors on 
its activities.

The Audit and Risk Committee 
oversees how Management monitors 
compliance with risk management 
policies and procedures and 
reviews the adequacy of the risk 
management framework in relation 
to the risks.

The main risks arising from the 
consolidated entity’s financial 
instruments are currency risk, 
credit risk, liquidity risk and cash flow 
interest rate risk.

The consolidated entity seeks to 
minimise the effects of these risks, 
where deemed appropriate, by using 
derivative financial instruments to 
hedge these risk exposures. The use 
of financial derivatives is governed 
by the consolidated entity’s policies 
on foreign exchange risk, credit 
risk, the use of financial derivatives 
and non‑derivative financial 
instruments, and the investment of 
excess liquidity. The consolidated 
entity does not enter into or trade 
financial instruments, including 
derivative financial instruments, 
for speculative purposes.

Market risk

The consolidated entity’s activities 
expose it primarily to the financial 
risks of changes in foreign currency 
exchange rates and cash flow 
interest rate risks. The consolidated 
entity enters into foreign exchange 
forward contracts to hedge the 
exchange rate risk arising from 
transactions not recorded in an 
entity’s functional currency.

Note 24: 
Financial instruments

72

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 24: Financial instruments (cont.)

Foreign currency risk management

The consolidated entity undertakes certain transactions denominated in foreign currencies, hence exposures to 
exchange rate fluctuations arise. Exchange rate exposures are managed within approved policy parameters utilising 
forward foreign exchange contracts.

The carrying amount of the consolidated entity’s foreign currency denominated monetary assets and monetary liabilities 
at the reporting date that are denominated in a currency that is different to the functional currency of the respective 
entities undertaking the transactions is as follows:

In thousands of AUD

US Dollar

Euro

UK Sterling

Consolidated

Liabilities

Assets

2016

62

‑

‑

2015

56

‑

‑

2016

5,380

689

1

2015

1,949

2,450

1

Foreign currency sensitivity

At 30 June 2016, if the US Dollar, Euro and UK sterling weakened or strengthened against the Australian dollar by the 
percentage shown, with all other variables held constant, net profit for the year would increase (decrease) by:

In thousands of AUD

US Dollar Impact

Euro Impact

UK Sterling Impact

Change in currency (i) ‑ 10% decrease

US Dollar Impact

Euro Impact

UK Sterling Impact

Change in currency (i) ‑ 10% increase

Consolidated

Net profit

Retained earnings

2016

591

77

‑

(483)

(63)

‑

2015

272

210

‑

(223)

(172)

‑

2016

591

77

‑

(483)

(63)

‑

2015

272

210

‑

(223)

(172)

‑

(i) This has been based on the change in the exchange rate against the Australian dollar in the financial years ended 30 June 2016 and 30 June 2015.

The sensitivity analysis has been based on the sensitivity rates used when reporting foreign currency risk internally to 
key management personnel and represents management’s assessment of the possible change in foreign exchange rates 
based on historical volatility.

In management’s opinion, the sensitivity analysis is not fully representative of the inherent foreign exchange risk as 
the year end exposure does not necessarily reflect the exposure during the course of the year. The consolidated entity 
includes certain subsidiaries whose functional currencies are different to the consolidated entity presentation currency. 
The main operating entities outside of Australia are based in the United States, the United Kingdom and Singapore. 
As stated in the consolidated entity’s accounting policies per Note 1, on consolidation the assets and liabilities of these 
entities are translated into Australian dollars at exchange rates prevailing at the year end date. The income and expenses 
of these entities is translated at the average exchange rates for the year. Exchange differences arising are classified as 
equity and are transferred to a foreign exchange translation reserve. The consolidated entity’s future reported profits 
could therefore be impacted by changes in rates of exchange between the Australian Dollar and the United States Dollar 
and the Australian Dollar and the UK Sterling.

73

Integrated Research and its controlled entities Annual Report 2016Note 24: Financial instruments (cont.)

Forward foreign exchange contracts 

The consolidated entity is exposed to foreign currency risk on sales and purchases that are denominated in a currency 
other than the AUD. The currencies giving rise to this risk are primarily United States Dollar, UK Sterling and the Euro. 

The consolidated entity uses forward exchange contracts to hedge its foreign currency risk. The forward exchange 
contracts have maturities of less than two years after the year end date.  

The consolidated entity classifies its forward exchange contracts hedging forecasted transactions as cash flow hedges 
and measures them at fair value. The following table details the forward foreign currency contracts outstanding as at 
reporting date: 

Average 
Exchange Rate

Foreign Currency

Contract Value

Fair Value

Outstanding 
contracts

2016

2015

2016
FC’000

2015
FC’000

2016
A$’000

2015
A$’000

2016
A$’000

2015
A$’000

Consolidated

Sell US Dollar

Less than 3 months

3 to 6 months

6 to 9 months

9 to 12 months

Sell Euros

Less than 3 months

3 to 6 months

6 to 9 months

9 to 12 months

Sell Sterling

Less than 3 months

3 to 6 months

6 to 9 months

9 to 12 months

0.72

0.73

0.73

0.74

0.65

0.64

0.65

0.66

0.52

0.53

0.53

0.51

0.84

0.84

0.76

0.77

0.69

0.67

0.68

‑

0.54

0.50

0.50

0.49

1,650

1,400

1,150

1,050

2,850

1,200

1,850

1,950

2,287

1,914

1,581

1,419

3,378

1,431

2,436

2,536

240

50

125

130

100

25

50

100

370

95

175

‑

250

100

100

75

370

78

192

198

192

47

95

196

534

141

259

‑

461

198

199

152

61

20

21

(10)

10

2

1

(2)

11

2

3

13

(334)

(141)

(1)

(39)

(3)

1

1

‑

(50)

(7)

(8)

(3)

132

(584)

These hedge assets and liabilities are classified as a level 2 fair value measurement, being derived from inputs provided 
from financial institutes, rather than quoted prices that are observable for the asset either directly (ie as prices) 
or indirectly (i.e. derived from prices). The fair value measurement of the OTC forward contact would not qualify as Level 1 
as there is not a quoted price for the actual contract, even though data used to value the contract may be derived 
entirely from active foreign‑exchange and interest‑rate market.

Interest rate risk management

The consolidated entity is exposed to interest rate risk on the cash held in bank deposits. Cash in bank and term deposits 
of $9,192,000 were held by the consolidated entity at the reporting date, attracting an average interest rate of 1.70% 
(2015: 2.36%). If interest rates had been 50 basis points higher or lower and all other variables were held constant, 
the consolidated entity’s net profit would increase/(decrease) by +/‑$45,960 (2015: +/‑ $79,855).

74

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 24: Financial instruments (cont.)

Credit risk management

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the 
consolidated entity. The consolidated entity has adopted a policy of only dealing with creditworthy counterparties and 
obtaining sufficient collateral where appropriate, as a means of mitigating the risk of financial loss from defaults.

Trade receivables consist of a large number of customers, spread across diverse industries and geographical areas. 
The largest single counterparty exposure with any one customer is with Avaya with a receivable balance at 30 June 2016 
of $7.0 million (2015: $7.23 million). Ongoing credit evaluation is performed on the financial condition of accounts.

The maximum expense to credit risk at the reporting date is the carrying value of each class of financial assets described 
at Note 11.

The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with 
high credit ratings assigned by international credit‑rating agencies.

Liquidity risk management

Ultimate responsibility for liquidity risk management rests with the board of directors, who have built an appropriate 
liquidity risk management framework for the management of the consolidated entity’s short, medium and long‑term 
funding and liquidity management requirements.

The consolidated entity manages liquidity risk by maintaining adequate reserves, by continuously monitoring forecast 
and actual cash flows and matching the maturity profiles of financial assets and liabilities.

All creditor and other payables shown in Note 18 for both 2016 and 2015 carry no interest obligation. 

Fair value of financial instruments

The carrying value of financial assets and financial liabilities of the consolidated entity is a reasonable approximation of 
their fair value. The fair value of non‑current debtors for 2016 are presented in the following table:

In thousands of AUD

Non‑current debtors

Consolidated

Carrying amount

Fair value

23,373

23,373

23,980

23,980

For non‑current trade debtors Integrated Research has considered a discount rate to recognise the net present value 
of the debtors. Level 3 inputs have been considered including corporate borrowing rates, size of the customer and 
jurisdiction of the customer. A discounted cashflow model was used to derive the fair value. The range of discount rates 
was between 3.5% to 5.5%. A 1% increase in the discount rate would lower the fair value of non‑current receivables by 
approximately $216,000. The carrying value of non‑current trade debtors for 2015 of the consolidated entity was a 
reasonable approximation of their fair value.

75

Integrated Research and its controlled entities Annual Report 2016Note 25: 
Operating leases 

Non‑cancellable operating lease rentals is for office space with payables as follows:

In thousands of AUD

Less than one year

Between one and five years

Greater than five years

Consolidated

2016

1,332

2,403

‑

3,375

2015

1,475

2,663

132

4,270

Note 26: 
Consolidated entities

Country of 
incorporation

Ownership interest

2016

2015

Parent entity:

Integrated Research Limited

Australia

Subsidiaries of Integrated 
Research Limited:

Integrated Research Inc

Integrated Research Singapore 
Pte Limited

USA

Singapore

100%

100%

100%

100%

Integrated Research UK Limited

UK

100%

100%

Subsidiaries of Integrated Research 
UK Limited:

Integrated Research Germany GmbH

Germany

100%

‑

In thousands of AUD

Profit for the year

Depreciation and amortisation

Provision for doubtful debts

Interest received

Interest paid

Share‑based payments expense

Net exchange differences

Change in operating assets and liabilities:

Consolidated

2016

16,029

10,636

1,008

(154)

120

655

(70)

2015

14,251

9,114

(6)

(297)

‑

728

(66)

(Increase)/decrease in trade debtors

(15,125)

(15,409)

(Increase)/decrease in future income tax benefit

(Increase)/decrease in other operating assets

Increase/(decrease) in trade and other payables

Increase/(decrease) in other operating liabilities

Increase/(decrease) in provision for income 
taxes payable

Increase/(decrease) in provision for deferred 
income taxes

Increase/(decrease) in other provisions

Net cash from operating activities

(150)

(286)

1,272

2,933

121

94

3,167

7,154

(1,515)

1,481

492

373

744

343

16,218

21,419

Note 27: 
Reconciliation of cash flows 
from operating activities 

76

Integrated Research and its controlled entities Annual Report 2016Financial StatementsNote 28: 
Key management 
personnel disclosures

Key management personnel compensation

The key management personnel compensation are as follows:

In AUD

Short‑term benefits

Post‑employment benefits

Long term benefit

Equity compensation benefits

Consolidated

2016

2015

3,470,104

3,248,694

196,825

31,561

171,284

42,264

291,597

436,035

3,990,087

3,898,277

Apart from the details disclosed in this note, no director has entered into a material 
contract with the consolidated entity since the end of the previous financial year 
and there were no material contracts involving directors’ interests existing at 
year‑end. 

Note 29: 
Related parties

At 30 June 2016 Mr Steve Killelea, the Chairman of the Company, owned either 
directly or indirectly 52.71% of the Company (2015: 55.89%).

Note 30: 
Parent entity disclosures

In thousands of AUD

Financial Position

Assets

Current assets

Non‑current assets

Total Assets

Liabilities

Current Liabilities

Non‑current liabilities

Total Liabilities

Net Assets

Equity

Issued Capital

Employee benefits Reserve

Hedging reserve

Retained Earnings

Total Equity

Parent Entity

2016

2015

28,047

24,050

17,979

46,026

18,928

42,978

8,612

4,684

13,296

32,730

1,667

2,161

50

28,852

32,730

7,295

5,167

12,462

30,516

1,667

1,571

(197)

27,475

30,516

77

Integrated Research and its controlled entities Annual Report 2016Note 30: 
Parent entity disclosures 
(cont.)

In thousands of AUD

Financial Performance

Profit for the year

Other comprehensive income

Total comprehensive income

Investments in subsidiaries are included at cost.

Parent Entity

2016

2015

13,283

247

13,530

13,412

(317)

13,095

Note 31: 
Subsequent events

Dividends

For dividends declared after 30 June 2016 see Note 23 in the financial statements. 
The financial effect of dividends declared and paid after 30 June 2016 have 
not been brought to account in the financial statements for the year ended 
30 June 2016 and will be recognised in subsequent financial reports.

78

Integrated Research and its controlled entities Annual Report 2016Financial StatementsDirectors’ declaration

Directors’ 
declaration

In accordance with a resolution of the directors of Integrated Research Limited, 
we state that:

1. 

In the opinion of the directors: 

(a) the financial statements and notes of Integrated Research Limited for 
the financial year ended 30 June 2016 are in accordance with the 
Corporations Act 2001, including: 

(i)  giving a true and fair view of the consolidated entity’s financial 
position as at 30 June 2016 and of its performance for the year 
ended on that date; and 

(ii)  complying with Accounting Standards and the Corporations 

Regulations 2001; 

(b) the financial statements and notes also comply with International 

Financial Reporting Standards as disclosed in Note 1; and 

(c) there are reasonable grounds to believe that the Company will be able 

to pay its debts as and when they become due and payable. 

2.  This declaration has been made after receiving the declarations required 

to be made to the directors by the chief executive officer and chief financial 
officer in accordance with section 295A of the Corporations Act 2001 for 
the financial year ended 30 June 2016. 

On behalf of the board.

Steve Killelea 
Chairman

Darc Rasmussen 
Chief Executive Officer

North Sydney, 22 August 2016

North Sydney, 22 August 2016

79

Integrated Research and its controlled entities Annual Report 2016Independent Auditor’s Report

80

Integrated Research and its controlled entities Annual Report 201627 to 37

81

Integrated Research and its controlled entities Annual Report 2016Independent Auditor’s Report

82

Integrated Research and its controlled entities Annual Report 2016Class of equity security

Ordinary shares

Shares

Options

Performance 
Rights

 864 

 2,222 

 987 

 1,204 

 74 

 5,351 

‑

‑

‑

‑

‑

‑

‑

14

21

25

5

65

Units % of Units

ASX additional information

Shareholder information

Analysis of numbers of equity security holders by size of holding

As at September 2016

1 ‑1,000

1,001 ‑ 5,000

5,001 ‑ 10,000

10,001 ‑ 100,000

100,001 and over

Fully Paid Ordinary Shares (Total)

As of 13 September 2016

Rank Name

1. MR STEPHEN JOHN KILLELEA

2. NATIONAL NOMINEES LIMITED

3. MR ANDREW RHYS RUTHERFORD

89,497,339

5,629,590

3,385,869

1,995,000

1,931,944

1,592,793

1,458,743

1,365,222

840,086

678,433

597,945

4.

5.

RBC INVESTOR SERVICES AUSTRALIA NOMINEES PTY LIMITED 

J P MORGAN NOMINEES AUSTRALIA LIMITED

6. UBS NOMINEES PTY LTD

7.

CITICORP NOMINEES PTY LIMITED

8. HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED

9. CUSTODIAL SERVICES LIMITED 

10. ABN AMRO CLEARING SYDNEY NOMINEES PTY LTD 

11.

FORSYTH BARR CUSTODIANS LTD 

12. MR KEVIN JOHN CAIRNS + MRS CATHERINE VALERIE CAIRNS 

580,000

13. BELL POTTER NOMINEES LTD 

542,000

14. MR GARY RONALD POOLE + MRS LEIGH MARGARET POOLE 

513,915

15. MR GARY RONALD POOLE + MRS LEIGH MARGARET POOLE 

486,085

16. KEY GLORY INVESTMENTS PTY LTD 

17.

FERGFAM NOMINEES PTY LTD 

18. BEEBEE HOLDINGS PTY LTD

19. WOODVILLE SUPER PTY LIMITED 

20. B & R JAMES INVESTMENTS PTY LIMITED 

440,812

375,263

350,000

350,000

340,000

52.47

3.30

1.98

1.17

1.13

0.93

0.86

0.80

0.49

0.40

0.35

0.34

0.32

0.30

0.28

0.26

0.22

0.21

0.21

0.20

83

Integrated Research and its controlled entities Annual Report 2016ASX additional information

Unquoted equity securities

Option issued under the Integrated Research Limited 
Employee Option Plan to take up ordinary shares

Number 
on issue

Number 
of holders

‑* 

‑

65

Performance Rights issued under the Integrated Research Limited Performance Rights and 
Option Plan to take up ordinary shares

2,288,800** 

* Number of unissued ordinary shares under the Options.

** Number of unissued ordinary shares under the Performance Rights.

On‑market buy‑back 

There is no current on‑market buy‑back.

Substantial holders

Substantial holders in the Company are set below:

Stephen John Killelea*

* Include direct and indirect holdings.

Voting rights

Number held Percentage

89,834,951 

52.67

The voting rights attaching to each class of equity securities are set out below:

1.  Ordinary shares. 

On a show of hands every member present at a meeting in person or proxy shall have one vote and upon a poll each 
share have one vote.

2.  Options. 

No voting rights.

3.  Performance rights.

4.  No voting rights.

Other information

Integrated Research Limited, incorporated and domiciled in Australia, is a publicly listed Company limited by shares.

84

Integrated Research and its controlled entities Annual Report 2016 
Nothing is as constant as change.

Nothing is as constant as change.

As IR celebrates another year of record growth 

As IR celebrates another year of record growth 

we’re making sure our global customers can 

we’re making sure our global customers can 

interact and transact in a frictionless way.

interact and transact in a frictionless way.

In the age of digital transformation we bring 

In the age of digital transformation we bring 

a thousand points of reference into a single 

a thousand points of reference into a single 

point of view.

point of view.

Corporate
Corporate
directory
directory

Directors

Directors

Steve Killelea
Non‑Executive Director & Chairman

Steve Killelea
Non‑Executive Director & Chairman

Darc Dencker‑Rasmussen
Managing Director & CEO

Darc Dencker‑Rasmussen
Managing Director & CEO

Share Registry
Computershare

Share Registry
Computershare

Solicitors
Ashurst
Level 11, 5 Martin Place
Sydney NSW 2000

Solicitors
Ashurst
Level 11, 5 Martin Place
Sydney NSW 2000

Nick Abrahams
Nick Abrahams
Non‑Executive Director
Non‑Executive Director

Alan Baxter
Alan Baxter
Non‑Executive Director
Non‑Executive Director

Paul Brandling
Paul Brandling
Non‑Executive Director
Non‑Executive Director

Garry Dinnie
Garry Dinnie
Non‑Executive Director
Non‑Executive Director

Peter Lloyd
Peter Lloyd
Non‑Executive Director
Non‑Executive Director

Company Secretary
David Purdue

Company Secretary
David Purdue

Registered Offi  ce
Registered Offi  ce
Level 9, 100 Pacifi c Highway
Level 9, 100 Pacifi c Highway
North Sydney NSW 2060
North Sydney NSW 2060
T. +61 (2) 9966 1066
T. +61 (2) 9966 1066

Bankers
National Australia Bank
Westpac Banking Corporation

Bankers
National Australia Bank
Westpac Banking Corporation

Securities Exchange Listing
Australian Securities Exchange
Code: IRI

Securities Exchange Listing
Australian Securities Exchange
Code: IRI

Country of Incorporation
Integrated Research Limited,
incorporated and domiciled in
Australia, is a publicly listed
company limited by shares.

Country of Incorporation
Integrated Research Limited,
incorporated and domiciled in
Australia, is a publicly listed
company limited by shares.

Notice of Annual General Meeting
Notice of Annual General Meeting
The Annual General Meeting of
The Annual General Meeting of
Integrated Research Limited will be
Integrated Research Limited will be
held on:
held on:

Friday 25 November 2016
The Mint
10 Macquarie Street, Sydney
at 3:00pm

Friday 25 November 2016
The Mint
10 Macquarie Street, Sydney
at 3:00pm

This Annual Report is printed on Titan Plus Satin. Fibre is sourced from certifi ed and well managed forests in compliance with the

This Annual Report is printed on Titan Plus Satin. Fibre is sourced from certifi ed and well managed forests in compliance with the

4847 Designed and Produced by RDA Creative www.rda.com.au

4847 Designed and Produced by RDA Creative www.rda.com.au

environmental and social standards of the FSC® Council.

environmental and social standards of the FSC® Council.